FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Yannarelli, G
   Pacienza, N
   Montanari, S
   Santa-Cruz, D
   Viswanathan, S
   Keating, A
AF Yannarelli, Gustavo
   Pacienza, Natalia
   Montanari, Sonia
   Santa-Cruz, Diego
   Viswanathan, Sowmya
   Keating, Armand
TI OCT4 expression mediates partial cardiomyocyte reprogramming of
   mesenchymal stromal cells
SO PLOS ONE
LA English
DT Article
ID ACUTE MYOCARDIAL-INFARCTION; EMBRYONIC STEM-CELLS; BONE-MARROW;
   CARDIAC-FUNCTION; FUNCTIONAL CARDIOMYOCYTES; DIFFERENTIATION CAPACITY;
   INDUCED PLURIPOTENCY; DIRECT CONVERSION; EMERGING CONCEPTS; PROGENITOR
   CELLS
AB Mesenchymal stem/stromal cells (MSCs) are in numerous cell therapy clinical trials, including for injured myocardium. Acquisition of cardiomyocyte characteristics by MSCs may improve cardiac regeneration but the mechanisms regulating this process are unclear. Here, we investigated whether the pluripotency transcription factor OCT4 is involved in the activation of cardiac lineage genetic programs in MSCs. We employed our established co-culture model of MSCs with rat embryonic cardiomyocytes showing co-expression of cardiac markers on MSCs independent of cell fusion. Bone marrow-derived MSCs were isolated from transgenic mice expressing GFP under the control of the cardiac-specific amyosin heavy chain promoter. After 5 days of co-culture, MSCs expressed cardiac specific genes, including Nkx2.5, atrial natriuretic factor and a-cardiac actin. The frequency of GFP+cells was 7.6 +/- 1.9%, however, these cells retained the stromal cell phenotype, indicating, as expected, only partial differentiation. Global OCT4 expression increased 2.6 +/- 0.7-fold in co-cultured MSCs and of interest, 87-5% vs 79-4% of MSCs expressed OCT4 by flow cytometry in controls and after co-culture, respectively. Consistent with the latter observation, the GFP+ cells did not express nuclear OCT4 and showed a significant increase in OCT4 promoter methylation compared with undifferentiated MSCs (92% vs 45%), inferring that OCT4 is regulated by an epigenetic mechanism. We further showed that siRNA silencing of OCT4 in MSCs resulted in a reduced frequency of GFP+ cells in co-culture to less than 1%. Our data infer that OCT4 expression may have a direct effect on partial cardiomyocyte reprogramming of MSCs and suggest a new mechanism(s) associated with MSC multipotency and a requirement for crosstalk with the cardiac microenvironment.
C1 [Yannarelli, Gustavo; Montanari, Sonia; Viswanathan, Sowmya; Keating, Armand] Univ Hlth Network, Princess Margaret Canc Ctr, Cell Therapy Program, Toronto, ON, Canada.
   [Yannarelli, Gustavo; Pacienza, Natalia; Santa-Cruz, Diego] Univ Favaloro, CONICET, Inst Med Traslac Trasplante & Bioingn IMeTTyB, Lab Regulac Gen & Celulas Madre, Buenos Aires, DF, Argentina.
RP Yannarelli, G (reprint author), Univ Hlth Network, Princess Margaret Canc Ctr, Cell Therapy Program, Toronto, ON, Canada.; Yannarelli, G (reprint author), Univ Favaloro, CONICET, Inst Med Traslac Trasplante & Bioingn IMeTTyB, Lab Regulac Gen & Celulas Madre, Buenos Aires, DF, Argentina.
EM gyannarelli@favaloro.edu.ar
RI Yannarelli, Gustavo/J-6055-2019; Viswanathan, Sowmya/N-1983-2019
OI Yannarelli, Gustavo/0000-0003-1450-5483; Viswanathan,
   Sowmya/0000-0002-4552-0179; Bay, Line/0000-0002-9760-2977
FU Orsino Translational Research Laboratory of Princess Margaret Hospital;
   Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation of
   University Health Network; University of Toronto; Agencia Nacional de
   Promocion Cientffica y Tecnologica (ANPCyT) of Argentina
   [PICT-2014-1198]
FX This work was supported by the Orsino Translational Research Laboratory
   of Princess Margaret Hospital, by the Gloria and Seymour Epstein Chair
   in Cell Therapy and Transplantation of University Health Network and the
   University of Toronto held by AK, and by Grant PICT-2014-1198 from the
   Agencia Nacional de Promocion Cientffica y Tecnologica (ANPCyT) of
   Argentina held by GY.
CR Afzal MR, 2015, CIRC RES, V117, P558, DOI 10.1161/CIRCRESAHA.114.304792
   Ahuja P, 2007, PHYSIOL REV, V87, P521, DOI 10.1152/physrev.00032.2006
   Altun G, 2010, J CELL BIOCHEM, V109, P1, DOI 10.1002/jcb.22374
   Amado LC, 2005, P NATL ACAD SCI USA, V102, P11474, DOI 10.1073/pnas.0504388102
   Behfar A, 2010, J AM COLL CARDIOL, V56, P721, DOI 10.1016/j.jacc.2010.03.066
   Davani S, 2003, CIRCULATION, V108, P253, DOI 10.1161/01.cir.0000089186.09692.fa
   Dayan V, 2011, BASIC RES CARDIOL, V106, P1299, DOI 10.1007/s00395-011-0221-9
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Eguchi G, 1993, CURR OPIN CELL BIOL, V5, P1023, DOI 10.1016/0955-0674(93)90087-7
   Fisher SA, 2015, CIRC RES, V116, P1361, DOI 10.1161/CIRCRESAHA.116.304386
   FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267
   Gallo MP, 2007, J CELL BIOCHEM, V100, P86, DOI 10.1002/jcb.21012
   Gao YW, 2013, CELL STEM CELL, V12, P453, DOI 10.1016/j.stem.2013.02.005
   Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com
   Greco SJ, 2007, STEM CELLS, V25, P3143, DOI 10.1634/stemcells.2007-0351
   Halkos ME, 2008, BASIC RES CARDIOL, V103, P525, DOI 10.1007/s00395-008-0741-0
   Hao Q, 2015, CELL REPROGRAM, V17, P347, DOI 10.1089/cell.2015.0025
   Hermann A, 2010, CYTOTHERAPY, V12, P17, DOI 10.3109/14653240903313941
   Hodgkinson CP, 2016, CIRC RES, V118, P95, DOI 10.1161/CIRCRESAHA.115.305373
   Ieda M, 2010, CELL, V142, P375, DOI 10.1016/j.cell.2010.07.002
   Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003
   Li Q, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt213
   Liu TM, 2009, STEM CELLS DEV, V18, P1013, DOI 10.1089/scd.2008.0335
   Liu Y, 2011, STEM CELLS, V29, P2077, DOI 10.1002/stem.764
   Liu Y, 2010, CELL BIOL INT, V34, P1075, DOI 10.1042/CBI20100516
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Maniatis T, 1989, MOL CLONING LAB MANU, V2
   Merrell AJ, 2016, NAT REV MOL CELL BIO, V17, P413, DOI 10.1038/nrm.2016.24
   Nagura S, 2013, CELL REPROGRAM, V15, P471, DOI 10.1089/cell.2013.0002
   Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199
   Noiseux N, 2006, MOL THER, V14, P840, DOI 10.1016/j.ymthe.2006.05.016
   Nowbar AN, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2688
   Papp B, 2013, CELL, V152, P1324, DOI 10.1016/j.cell.2013.02.043
   Pei DQ, 2009, J BIOL CHEM, V284, P3365, DOI 10.1074/jbc.R800063200
   Pochampally RR, 2004, BLOOD, V103, P1647, DOI 10.1182/blood-2003-06-1967
   Prockop DJ, 2016, MATRIX BIOL, V51, P7, DOI 10.1016/j.matbio.2016.01.010
   Radzisheuskaya A, 2014, TRENDS CELL BIOL, V24, P275, DOI 10.1016/j.tcb.2013.11.010
   Rohde C, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-230
   Rompolas P, 2013, NATURE, V502, P513, DOI 10.1038/nature12602
   Rose RA, 2008, STEM CELLS, V26, P2884, DOI 10.1634/stemcells.2008-0329
   Rui YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep11056
   Sarugaser R, 2005, STEM CELLS, V23, P220, DOI 10.1634/stemcells.2004-0166
   SHIMAZAKI T, 1993, EMBO J, V12, P4489, DOI 10.1002/j.1460-2075.1993.tb06138.x
   Silva J, 2008, CELL, V132, P532, DOI 10.1016/j.cell.2008.02.006
   Singh A, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0341-0
   Song L, 2004, FASEB J, V18, P980, DOI 10.1096/fj.03-1100fje
   Sterneckert J, 2012, STEM CELLS, V30, P15, DOI 10.1002/stem.765
   Szabo E, 2010, NATURE, V468, P521, DOI 10.1038/nature09591
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tantin D, 2013, DEVELOPMENT, V140, P2857, DOI 10.1242/dev.095927
   Torper O, 2013, P NATL ACAD SCI USA, V110, P7038, DOI 10.1073/pnas.1303829110
   Ullah M, 2014, INT J BIOCHEM CELL B, V46, P124, DOI 10.1016/j.biocel.2013.11.010
   Wang Y, 2014, NAT IMMUNOL, V15, P1009, DOI 10.1038/ni.3002
   Yannarelli G, 2014, STEM CELL REV REP, V10, P304, DOI 10.1007/s12015-013-9483-y
   Yannarelli G, 2013, CELL TRANSPLANT, V22, P1651, DOI 10.3727/096368912X657675
   Yannarelli G, 2013, STEM CELLS, V31, P215, DOI 10.1002/stem.1262
   Yoon CH, 2010, CIRCULATION, V121, P2001, DOI 10.1161/CIRCULATIONAHA.109.909291
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105
NR 58
TC 0
Z9 0
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 7
PY 2017
VL 12
IS 12
AR e0189131
DI 10.1371/journal.pone.0189131
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FP0ZD
UT WOS:000417337800080
PM 29216265
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Song, YS
   Joo, HW
   Park, IH
   Shen, GY
   Lee, Y
   Shin, JH
   Kim, H
   Kim, KS
AF Song, Yi-Sun
   Joo, Hyun-Woo
   Park, In-Hwa
   Shen, Guang-Yin
   Lee, Yonggu
   Shin, Jeong Hun
   Kim, Hyuck
   Kim, Kyung-Soo
TI Bone marrow mesenchymal stem cell-derived vascular endothelial growth
   factor attenuates cardiac apoptosis via regulation of cardiac miRNA-23a
   and miRNA-92a in a rat model of myocardial infarction
SO PLOS ONE
LA English
DT Article
ID ISCHEMIC-HEART; FUNCTIONAL IMPROVEMENT; MOUSE MODEL; TRANSPLANTATION;
   MICRORNAS; VEGF; CARDIOMYOCYTES; EXPRESSION; ANGIOGENESIS; MECHANISMS
AB Bone marrow-mesenchymal stem cell (BM-MSC) therapy improves the recovery of cardiac function after myocardial infarction (MI); however, the underlying molecular mechanisms are not completely understood. Recent studies have shown that microRNAs (miRNAs) modulate the pathophysiology of cardiovascular diseases. Here, we investigated the mechanisms underlying the effects of BM-MSC-derived paracrine factors and cardiac miRNAs on myocardial regeneration after MI. In our study, MI was induced by permanent ligation of the left anterior descending (LAD) coronary artery. BM-MSCs transplanted in infarcted rats significantly downregulated the expression of miRNA-23a and miRNA-92a and inhibited apoptosis in the myocardium. An in vitro experiment showed that supernatant from BM-MSCs cultured under hypoxia contained higher levels of vascular endothelial growth factor (VEGF) than that from BM-MSCs under normoxia. In addition, inhibition of miRNA-23a and miRNA-92a reduced cardiac apoptosis. Moreover, the VEGF-containing BM-MSC supernatant inhibited miRNA-23a and miRNA-92a expression and reduced apoptotic signaling in cardiomyocytes under hypoxia. These effects were inhibited when the supernatant was treated with neutralizing antibodies against VEGF. Our results indicate that the paracrine factor, VEGF, derived from transplanted BM-MSCs, regulated the expression of miRNAs such as miRNA-23a and miRNA-92a and exerted anti-apoptotic effects in cardiomyocytes after MI.
C1 [Song, Yi-Sun; Joo, Hyun-Woo; Park, In-Hwa; Kim, Kyung-Soo] Hanyang Univ, Grad Sch Biomed Sci & Engn, Seoul, South Korea.
   [Shen, Guang-Yin; Kim, Kyung-Soo] Hanyang Univ, Coll Med, Dept Internal Med, Seoul, South Korea.
   [Lee, Yonggu; Shin, Jeong Hun] Hanyang Univ, Guri Hosp, Dept Internal Med, Guri, South Korea.
   [Kim, Hyuck] Hanyang Univ, Coll Med, Dept Thorac & Cardiovasc Surg, Seoul, South Korea.
RP Kim, KS (reprint author), Hanyang Univ, Grad Sch Biomed Sci & Engn, Seoul, South Korea.
EM kskim@hanyang.ac.kr
RI Lee, Yonggu/Q-3832-2018
OI Lee, Yonggu/0000-0002-3757-3692
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education [NRF-2015R1D1A1A02062008]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education (NRF-2015R1D1A1A02062008).
CR Amado LC, 2005, P NATL ACAD SCI USA, V102, P11474, DOI 10.1073/pnas.0504388102
   Amsalem Y, 2007, CIRCULATION, V116, pI38, DOI 10.1161/CIRCULATIONAHA.106.680231
   Bonauer A, 2009, SCIENCE, V324, P1710, DOI 10.1126/science.1174381
   Bronnum H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056280
   Chen SL, 2004, AM J CARDIOL, V94, P92, DOI 10.1016/j.amjcard.2004.03.034
   Chhabra R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005848
   Chou SH, 2014, CELL TRANSPLANT, V23, P513, DOI 10.3727/096368914X678436
   Clifford DM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006536.pub3
   Condorelli G, 2014, J AM COLL CARDIOL, V63, P2177, DOI 10.1016/j.jacc.2014.01.050
   Fang CH, 2012, CELL TRANSPLANT, V21, P1687, DOI 10.3727/096368912X653039
   Feygin J, 2007, AM J PHYSIOL-HEART C, V293, pH1772, DOI 10.1152/ajpheart.00242.2007.
   Frost RJA, 2010, J CARDIOVASC TRANSL, V3, P280, DOI 10.1007/s12265-010-9173-y
   Gnecchi M, 2005, NAT MED, V11, P367, DOI 10.1038/nm0405-367
   Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com
   GOMEZ JP, 1994, PFLUG ARCH EUR J PHY, V428, P241, DOI 10.1007/BF00724503
   Gulyaeva LF, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0893-x
   Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838
   Hare JM, 2009, J AM COLL CARDIOL, V54, P2277, DOI 10.1016/j.jacc.2009.06.055
   Hinkel R, 2013, CIRCULATION, V128, P1066, DOI 10.1161/CIRCULATIONAHA.113.001904
   Hodgkinson CP, 2016, CIRC RES, V118, P95, DOI 10.1161/CIRCRESAHA.115.305373
   Iekushi K, 2012, CIRCULATION, V125, P1765, DOI 10.1161/CIRCULATIONAHA.111.079699
   Imanishi Y, 2008, J MOL CELL CARDIOL, V44, P662, DOI 10.1016/j.yjmcc.2007.11.001
   Jin JY, 2009, EUR J HEART FAIL, V11, P147, DOI 10.1093/eurjhf/hfn017
   Karantalis V, 2015, CIRC RES, V116, P1413, DOI 10.1161/CIRCRESAHA.116.303614
   Katritsis DG, 2005, CATHETER CARDIO INTE, V65, P321, DOI 10.1002/ccd.20406
   Kilkenny C, 2012, VET CLIN PATH, V41, P27, DOI 10.1111/j.1939-165X.2012.00418.x
   Kishore R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060161
   Lee KM, 2012, BIOCHEM BIOPH RES CO, V428, P50, DOI 10.1016/j.bbrc.2012.09.145
   Liu LF, 2014, APOPTOSIS, V19, P19, DOI 10.1007/s10495-013-0899-2
   Markel TA, 2008, AM J PHYSIOL-HEART C, V295, pH2308, DOI 10.1152/ajpheart.00565.2008
   Marko SB, 2008, AM J PHYSIOL-HEART C, V294, pH2646, DOI 10.1152/ajpheart.00291.2008
   Matsubayashi K, 2003, CIRCULATION, V108, P219, DOI 10.1161/01.cir.0000087450.34497.9a
   Matsuura K, 2009, J CLIN INVEST, V119, P2204, DOI 10.1172/JCI37456
   Mazo M, 2008, EUR J HEART FAIL, V10, P454, DOI 10.1016/j.ejheart.2008.03.017
   Nagaya N, 2004, AM J PHYSIOL-HEART C, V287, pH2670, DOI 10.1152/ajpheart.01071.2003
   Neufeld G, 1999, FASEB J, V13, P9
   Nguyen BK, 2010, J CARDIOVASC TRANSL, V3, P547, DOI 10.1007/s12265-010-9171-0
   Papageorgiou N, 2012, CURR MED CHEM, V19, P2605, DOI 10.2174/092986712800493048
   Patten RD, 1998, AM J PHYSIOL-HEART C, V274, pH1812
   Port JD, 2011, PHYSIOL GENOMICS, V43, P1087, DOI 10.1152/physiolgenomics.00074.2011
   Ren XP, 2009, CIRCULATION, V119, P2357, DOI 10.1161/CIRCULATIONAHA.108.814145
   Romaine SPR, 2015, HEART, V101, P921, DOI 10.1136/heartjnl-2013-305402
   Seideman J, 2002, J IMMUNOL METHODS, V267, P165, DOI 10.1016/S0022-1759(02)00168-0
   Shi B, 2010, BMC CARDIOVASC DISOR, V10, DOI 10.1186/1471-2261-10-11
   Shin JH, 2014, CARDIOVASC DRUG THER, V28, P211, DOI 10.1007/s10557-014-6519-8
   Song YS, 2014, CELL TRANSPLANT
   Takahashi M, 2006, AM J PHYSIOL-HEART C, V291, pH886, DOI 10.1152/ajpheart.00142.2006
   Tang YL, 2004, REGUL PEPTIDES, V117, P3, DOI 10.1016/j.regpep.2003.09.005
   Thygesen K, 2012, J AM COLL CARDIOL, V60, P1581, DOI 10.1016/j.jacc.2012.08.001
   Uemura R, 2006, CIRC RES, V98, P1414, DOI 10.1161/01.RES.0000225952.61196.39
   van Rooij E, 2008, P NATL ACAD SCI USA, V105, P13027, DOI 10.1073/pnas.0805038105
   van Rooij E, 2006, P NATL ACAD SCI USA, V103, P18255, DOI 10.1073/pnas.0608791103
   Vanlangenakker N, 2011, CELL DEATH DIFFER, V18, P656, DOI 10.1038/cdd.2010.138
   Weir C, 2008, HEART LUNG CIRC, V17, P395, DOI 10.1016/j.hlc.2008.01.006
   Zhang BS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100298
NR 55
TC 5
Z9 5
U1 1
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 29
PY 2017
VL 12
IS 6
AR e0179972
DI 10.1371/journal.pone.0179972
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EZ3JX
UT WOS:000404608300083
PM 28662151
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Ye, JQ
   Gaur, M
   Zhang, Y
   Sievers, RE
   Woods, BJ
   Aurigui, J
   Bernstein, HS
   Yeghiazarians, Y
AF Ye, Jianqin
   Gaur, Meenakshi
   Zhang, Yan
   Sievers, Richard E.
   Woods, Brandon J.
   Aurigui, Julian
   Bernstein, Harold S.
   Yeghiazarians, Yerem
TI Treatment with hESC-Derived Myocardial Precursors Improves Cardiac
   Function after a Myocardial Infarction
SO PLOS ONE
LA English
DT Article
ID MESENCHYMAL STEM-CELLS; RAT HEARTS; TRANSPLANTATION; CARDIOMYOCYTES;
   THERAPY; PROTECTION; INJECTION; CYTOKINES; REPAIR
AB Background
   We previously reported the generation of a reporter line of human embryonic stem cells (hESCs) with enhanced green fluorescent protein (eGFP) expression driven by the alpha-myosin heavy chain (alpha MHC) promoter. The GFP(+)/alpha MHC+ cells derived from this cell line behave as multipotent, human myocardial precursors (hMPs) in vitro. In this study, we evaluated the therapeutic effects of GFP(+)/alpha MHC+ cells isolated from the reporter line in a mouse model of myocardial infarction (MI).
   Methods
   MI was generated in immunodeficient mice. hMPs were injected into murine infarcted hearts under ultrasound guidance at 3 days post-MI. Human fetal skin fibroblasts (hFFs) were injected as control. Cardiac function was evaluated by echocardiography. Infarct size, angiogenesis, apoptosis, cell fate, and teratoma formation were analyzed by immunohistochemical staining.
   Results
   Compared with control, hMPs resulted in improvement of cardiac function post-MI with smaller infarct size, induced endogenous angiogenesis, and reduced apoptosis of host cardiomyocytes at the peri-infarct zone at 28 days post-MI.
   Conclusion
   Intramyocardial injection of hMPs improved cardiac function post-MI. The engraftment rate of these cells in the myocardium post-MI was low, suggesting that the majority of effect occurs via paracrine mechanisms.
C1 [Ye, Jianqin; Gaur, Meenakshi; Zhang, Yan; Sievers, Richard E.; Woods, Brandon J.; Yeghiazarians, Yerem] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
   [Aurigui, Julian; Bernstein, Harold S.; Yeghiazarians, Yerem] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA.
   [Bernstein, Harold S.; Yeghiazarians, Yerem] Univ Calif San Francisco, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA 94143 USA.
RP Yeghiazarians, Y (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
EM yeghiaza@medicine.ucsf.edu
FU California Institute of Regenerative Medicine [RC1-00104-1]
FX This work was supported by a grant from the California Institute of
   Regenerative Medicine to HSB and YY (RC1-00104-1).
CR Bartunek J, 2013, J AM COLL CARDIOL, V61, P2329, DOI 10.1016/j.jacc.2013.02.071
   Bernstein H. S., 2010, J VIS EXP
   Bernstein HS, 2012, REGEN MED, V7, P697, DOI [10.2217/RME.12.46, 10.2217/rme.12.46]
   Caspi O, 2007, J AM COLL CARDIOL, V50, P1884, DOI 10.1016/j.jacc.2007.07.054
   Chimenti I, 2010, CIRC RES, V106, P971, DOI 10.1161/CIRCRESAHA.109.210682
   Chong JJH, 2014, NATURE, V510, P273, DOI 10.1038/nature13233
   Ebelt H, 2007, STEM CELLS, V25, P236, DOI 10.1634/stemcells.2006-0374
   Gnecchi M, 2005, NAT MED, V11, P367, DOI 10.1038/nm0405-367
   Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com
   Hare JM, 2012, JAMA-J AM MED ASSOC, V308, P2369, DOI 10.1001/jama.2012.25321
   Hatzistergos KE, 2010, CIRC RES, V107, P913, DOI 10.1161/CIRCRESAHA.110.222703
   Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC
   Laflamme MA, 2007, NAT BIOTECHNOL, V25, P1015, DOI 10.1038/nbt1327
   Loffredo FS, 2011, CELL STEM CELL, V8, P389, DOI 10.1016/j.stem.2011.02.002
   Nussbaum J, 2007, FASEB J, V21, P1345, DOI 10.1096/fj.06-6769com
   Ritner C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016004
   Segers VFM, 2008, NATURE, V451, P937, DOI 10.1038/nature06800
   Springer ML, 2005, AM J PHYSIOL-HEART C, V289, pH1307, DOI 10.1152/ajpheart.00164.2005
   Stevens KR, 2009, P NATL ACAD SCI USA, V106, P16568, DOI 10.1073/pnas.0908381106
   Sui RQ, 2011, STEM CELL REV REP, V7, P172, DOI 10.1007/s12015-010-9131-8
   Takagawa J, 2007, J APPL PHYSIOL, V102, P2104, DOI 10.1152/japplphysiol.00033.2007
   van Laake LW, 2010, CELL MOL LIFE SCI, V67, P277, DOI 10.1007/s00018-009-0179-z
   van Laake LW, 2009, STEM CELL RES, V3, P106, DOI 10.1016/j.scr.2009.05.004
   Venugopal JR, 2012, J R SOC INTERFACE, V9, P1, DOI 10.1098/rsif.2011.0301
   Ye JQ, 2014, J CARDIOVASC PHARM, V63, P85, DOI 10.1097/FJC.0b013e318299ebc0
   Ye JQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030329
   Yeghiazarians Y, 2012, CYTOTHERAPY, V14, P223, DOI 10.3109/14653249.2011.623690
   Yeghiazarians Y, 2009, MOL THER, V17, P1250, DOI 10.1038/mt.2009.85
NR 28
TC 6
Z9 6
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 31
PY 2015
VL 10
IS 7
AR e0131123
DI 10.1371/journal.pone.0131123
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CO0JY
UT WOS:000358838400007
PM 26230835
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Yao, Y
   Huang, J
   Geng, YJ
   Qian, HY
   Wang, F
   Liu, XH
   Shang, MS
   Nie, SP
   Liu, NA
   Du, X
   Dong, JZ
   Ma, CS
AF Yao, Yan
   Huang, Ji
   Geng, Yongjian
   Qian, Haiyan
   Wang, Fan
   Liu, Xiaohui
   Shang, Meisheng
   Nie, Shaoping
   Liu, Nian
   Du, Xin
   Dong, Jianzeng
   Ma, Changsheng
TI Paracrine Action of Mesenchymal Stem Cells Revealed by Single Cell Gene
   Profiling in Infarcted Murine Hearts
SO PLOS ONE
LA English
DT Article
ID ACUTE MYOCARDIAL-INFARCTION; BONE-MARROW; PROGENITOR CELLS;
   GROWTH-FACTOR; ISCHEMIC CARDIOMYOPATHY; FUNCTIONAL IMPROVEMENT; CARDIAC
   PROTECTION; MONONUCLEAR-CELLS; DOUBLE-BLIND; IN-VITRO
AB Background
   Mesenchymal stem cells (MSCs) have been recently demonstrated as a promising stem cell type to rescue damaged myocardium after acute infarction. One of the most important mechanisms underlying their therapeutic effects is the secretion of paracrine factors. However, the expression profile of paracrine factors of MSCs in infarcted hearts, especially at single cell level, is poorly defined.
   Methods and Results
   We aimed to depict the transcriptional profile of paracrine factors secreted by MSCs in vivo, with particular interest in the comparison between normal and infarcted hearts. Bone marrow mesenchymal stem cells were isolated and injected into mice hearts immediately after infarction surgery. Bioluminescence imaging (BLI) indicated a proportion of cells still alive even up to 10 days post surgery. Paralleled with survived cells, cardiac function was significantly improved after MSC injection compared to that in PBS-injected mice, indicated by MRI and histology. Despite increased number of vessels in MSC-injected hearts, endothelial cells and cardiomyocytes transdifferentiation were not observed in infarcted hearts 5 days after infarction. Furthermore, laser capture microdissection (LCM) followed by high through-put real time PCR was employed in our study, uncovering that the injected MSCs, compared to local cardiomyocytes, displayed elevated levels of secreted factors. To further investigate the regulation of those factors, we performed single cell analysis to dissect the gene expression profile of MSCs at single cell level in infarcted and normal hearts, respectively. Consistent with the in vivo observation, a similar regulation pattern of those factors was detected in cultured MSCs under hypoxia.
   Conclusions
   Our study, for the first time, elucidated gene expression profiles, as well as regulation of paracrine factors, of MSCs at single cell level in vivo, indicating that paracrine factors from MSCs account for the improvement of cardiac function after infarction.
C1 [Yao, Yan; Huang, Ji; Liu, Xiaohui; Shang, Meisheng; Liu, Nian; Du, Xin; Dong, Jianzeng; Ma, Changsheng] Capital Med Univ, Beijing Anzhen Hosp, Beijing Inst Heart Lung & Blood Vessel Dis, Dept Cardiol, Beijing, Peoples R China.
   [Geng, Yongjian] Univ Texas Hlth Sci Ctr Houston, Sch Med, Dept Internal Med, Ctr Cardiovasc Biol & Atherosclerosis, Houston, TX 77030 USA.
   [Qian, Haiyan] Chinese Acad Med Sci, Natl Ctr Cardiovasc Dis, Fuwai Hosp, Ctr Coronary Heart Dis,Dept Cardiol,State Key Lab, Beijing 100730, Peoples R China.
   [Qian, Haiyan] Peking Union Med Coll, Beijing 100021, Peoples R China.
   [Wang, Fan] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
   [Nie, Shaoping] Capital Med Univ, Beijing Anzhen Hosp, Beijing Inst Heart Lung & Blood Vessel Dis, Emergency & Crit Care Ctr, Beijing, Peoples R China.
RP Yao, Y (reprint author), Capital Med Univ, Beijing Anzhen Hosp, Beijing Inst Heart Lung & Blood Vessel Dis, Dept Cardiol, Beijing, Peoples R China.
EM iceyaya614@163.com
RI Nie, Shaoping/K-1124-2019; Liu, Nian/M-5808-2019
FU National Natural Science Foundation of China [81200141, 81070091,
   81000130, 81000091]; Beijing Novel Program [2011081, Z131103000413116];
   Program of International S&T Cooperation Project of China
   [2013DFB30310]; "973" National Program on Key Basic Research Project of
   China [2013CB531105]
FX 2 This work was supported by grants from the National Natural Science
   Foundation of China (No. 81200141, 81070091, 81000130, 81000091),
   Beijing Novel Program (No. 2011081, Z131103000413116), Program of
   International S&T Cooperation Project of China (No. 2013DFB30310) and
   "973" National Program on Key Basic Research Project of China (No.
   2013CB531105).
CR Aicher A, 2003, CIRCULATION, V107, P2134, DOI 10.1161/01.CIR.0000062649.63838.C9
   Burchfield JS, 2008, CIRC RES, V103, P203, DOI 10.1161/CIRCRESAHA.108.178475
   Cantoni S, 2012, PHARMACOL RES, V65, P275, DOI 10.1016/j.phrs.2011.12.004
   Deuse T, 2009, CIRCULATION, V120, pS247, DOI 10.1161/CIRCULATIONAHA.108.843680
   Fang J, 2011, J MOL CELL CARDIOL, V51, P839, DOI 10.1016/j.yjmcc.2011.06.013
   Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826
   Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com
   Haider HK, 2008, CIRC RES, V103, P1300, DOI 10.1161/CIRCRESAHA.108.186742
   Hare JM, 2009, J AM COLL CARDIOL, V54, P2277, DOI 10.1016/j.jacc.2009.06.055
   Haynesworth SE, 1996, J CELL PHYSIOL, V166, P585, DOI 10.1002/(SICI)1097-4652(199603)166:3<585::AID-JCP13>3.3.CO;2-7
   Hu XY, 2008, J THORAC CARDIOV SUR, V135, P799, DOI 10.1016/j.jtcvs.2007.07.071
   Imanishi Y, 2008, J MOL CELL CARDIOL, V44, P662, DOI 10.1016/j.yjmcc.2007.11.001
   Jeevanantham V, 2012, CIRCULATION, V126, P551, DOI 10.1161/CIRCULATIONAHA.111.086074
   Kinnaird T, 2004, CIRCULATION, V109, P1543, DOI 10.1161/01.CIR.0000124062.31102.57
   Mirotsou M, 2011, J MOL CELL CARDIOL, V50, P280, DOI 10.1016/j.yjmcc.2010.08.005
   Narsinh KH, 2011, J CLIN INVEST, V121, P1217, DOI 10.1172/JCI44635
   Nygren JM, 2004, NAT MED, V10, P494, DOI 10.1038/nm1040
   Ohnishi S, 2007, STEM CELLS, V25, P1166, DOI 10.1634/stemcells.2006-0347
   Padin-Iruegas ME, 2009, CIRCULATION, V120, P876, DOI 10.1161/CIRCULATIONAHA.109.852285
   Pittenger MF, 2004, CIRC RES, V95, P9, DOI 10.1161/01.RES.0000135902.99383.6f
   Rubakhin SS, 2011, NAT METHODS, V8, pS20, DOI [10.1038/NMETH.1549, 10.1038/nmeth.1549]
   Schuleri KH, 2009, EUR HEART J, V30, P2722, DOI 10.1093/eurheartj/ehp265
   Shabbir A, 2010, AM J PHYSIOL-HEART C, V299, pH1428, DOI 10.1152/ajpheart.00488.2010
   Takahashi M, 2006, AM J PHYSIOL-HEART C, V291, pH886, DOI 10.1152/ajpheart.00142.2006
   Trachtenberg B, 2011, AM HEART J, V161, P487, DOI 10.1016/j.ahj.2010.11.024
   Uemura R, 2006, CIRC RES, V98, P1414, DOI 10.1161/01.RES.0000225952.61196.39
   van der Spoel TIG, 2011, CARDIOVASC RES, V91, P649, DOI 10.1093/cvr/cvr113
   Wang XH, 2009, STEM CELLS, V27, P3021, DOI 10.1002/stem.230
   Williams AR, 2011, CIRC RES, V109, P923, DOI 10.1161/CIRCRESAHA.111.243147
   Williams AR, 2011, CIRC RES, V108, P792, DOI 10.1161/CIRCRESAHA.111.242610
   Windmolders S, 2014, J MOL CELL CARDIOL, V66, P177, DOI 10.1016/j.yjmcc.2013.11.016
   Xu MF, 2007, J MOL CELL CARDIOL, V42, P441, DOI 10.1016/j.yjmcc.2006.10.009
   Yang YJ, 2008, EUR HEART J, V29, P1578, DOI 10.1093/eurheartj/ehn167
   Yang YJ, 2009, ARTERIOSCL THROM VAS, V29, P2076, DOI 10.1161/ATVBAHA.109.189662
   Zisa D, 2011, AM J PHYSIOL-HEART C, V301, pH2422, DOI 10.1152/ajpheart.00343.2011
NR 35
TC 15
Z9 15
U1 3
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 4
PY 2015
VL 10
IS 6
AR UNSP e0129164
DI 10.1371/journal.pone.0129164
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CJ7TC
UT WOS:000355701600091
PM 26043119
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Wang, XH
   Li, QL
   Hu, QS
   Suntharalingam, P
   From, AHL
   Zhang, JY
AF Wang, Xiaohong
   Li, Qinglu
   Hu, Qingsong
   Suntharalingam, Piradeep
   From, Arthur H. L.
   Zhang, Jianyi
TI Intra-Myocardial Injection of Both Growth Factors and Heart Derived
   Sca-1(+)/CD31(-) Cells Attenuates Post-MI LV Remodeling More Than Does
   Cell Transplantation Alone: Neither Intervention Enhances Functionally
   Significant Cardiomyocyte Regeneration
SO PLOS ONE
LA English
DT Article
ID MESENCHYMAL STEM-CELLS; INFARCTED MYOCARDIUM; VENTRICULAR-FUNCTION;
   ISCHEMIC-HEART; AKT; PROTECTION; APOPTOSIS; THERAPY; MULTIPOTENT;
   ACTIVATION
AB Insulin-like growth factor 1 (IGF-1) and hepatocyte growth factor (HGF) are two potent cell survival and regenerative factors in response to myocardial injury (MI). We hypothesized that simultaneous delivery of IGF+HGF combined with Sca-1(+)/CD31(-) cells would improve the outcome of transplantation therapy in response to the altered hostile microenvironment post MI. One million adenovirus nuclear LacZ-labeled Sca-1(+)/CD31(-) cells were injected into the peri-infarction area after left anterior descending coronary artery (LAD) ligation in mice. Recombinant mouse IGF-1+HGF was added to the cell suspension prior to the injection. The left ventricular (LV) function was assessed by echocardiography 4 weeks after the transplantation. The cell engraftment, differentiation and cardiomyocyte regeneration were evaluated by histological analysis. Sca-1(+)/CD31(-) cells formed viable grafts and improved LV ejection fraction (EF) (Control, 54.5+/-2.4; MI, 17.6+/-2 3.1; Cell, 28.2+/-4.2, n = 9, P<0.01). IGF+HGF significantly enhanced the benefits of cell transplantation as evidenced by increased EF (38.8+/-2.2; n = 9, P<0.01) and attenuated adverse structural remodeling. Furthermore, IGF+HGF supplementation increased the cell engraftment rate, promoted the transplanted cell survival, enhanced angiogenesis, and minimally stimulated endogenous cardiomyocyte regeneration in vivo. The in vitro experiments showed that IGF+HGF treatment stimulated Sca-1(+)/CD31(-) cell proliferation and inhibited serum free medium induced apoptosis. Supperarray profiling of Sca-1(+)/CD31(-) cells revealed that Sca-1(+)/CD31(-) cells highly expressed various trophic factor mRNAs and IGF+HGF treatment altered the mRNAs expression patterns of these cells. These data indicate that IGF-1+HGF could serve as an adjuvant to cell transplantation for myocardial repair by stimulating donor cell and endogenous cardiac stem cell survival, regeneration and promoting angiogenesis.
C1 [Wang, Xiaohong; Li, Qinglu; Hu, Qingsong; Suntharalingam, Piradeep; From, Arthur H. L.; Zhang, Jianyi] Univ Minnesota, Sch Med, Dept Med, Div Cardiovasc, Minneapolis, MN 55455 USA.
RP Wang, XH (reprint author), Univ Minnesota, Sch Med, Dept Med, Div Cardiovasc, Minneapolis, MN 55455 USA.
EM wangx270@umn.edu; zhang047@umn.edu
RI Zhang, Jianyi/N-1949-2018
OI Zhang, Jianyi/0000-0002-3955-6554
FU American Heart Association; Lillehei Institute; National Institutes of
   Health [NCRR P41 RR008079]; Department of Medicine (Cardiology Division)
   of the University of Minnesota;  [HL 67828];  [0750160Z]
FX This work was supported by an American Heart Association Grant-in Aid
   (X.W #0750160Z) and the Lillehei Institute and the Department of
   Medicine (Cardiology Division) of the University of Minnesota (X.W. and
   J.Z.), and HL 67828 (J.Z.) and support to the Center for Magnetic
   Resonance Research of the University of Minnesota by National Institutes
   of Health grant NCRR P41 RR008079 (to Kamil Ugurbil, PhD). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Akasaka Y, 2006, MODERN PATHOL, V19, P588, DOI 10.1038/modpathol.3800568
   Anversa P, 2005, BASIC RES CARDIOL, V100, P482, DOI 10.1007/s00395-005-0554-3
   Bialik S, 1997, J CLIN INVEST, V100, P1363, DOI 10.1172/JCI119656
   Crow MT, 2004, CIRC RES, V95, P957, DOI 10.1161/01.RES.0000148632.35500.d9
   Davis ME, 2006, P NATL ACAD SCI USA, V103, P8155, DOI 10.1073/pnas.0602877103
   Devin JK, 2008, CURR OPIN INVEST DR, V9, P983
   Donath S, 2006, CIRCULATION, V113, P1203, DOI 10.1161/CIRCULATIONAHA.105.576785
   Giordano FJ, 2001, P NATL ACAD SCI USA, V98, P5780, DOI 10.1073/pnas.091415198
   Gnecchi M, 2005, NAT MED, V11, P367, DOI 10.1038/nm0405-367
   Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826
   Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com
   Gnecchi M, 2009, STEM CELLS, V27, P971, DOI 10.1002/stem.12
   Guarita-Souza LC, 2006, CIRCULATION, V114, pI120, DOI 10.1161/CIRCULATIONAHA.105.000646
   Jayasankar V, 2003, CIRCULATION, V108, P230, DOI 10.1161/01.cir.0000087444.53354.66
   Kajstura J, 2005, CIRC RES, V96, P127, DOI 10.1161/01.RES.0000151843.79801.60
   Li Z, 2007, CIRCULATION, V116, pI46, DOI 10.1161/CIRCULATIONAHA.106.680561
   Linke A, 2005, P NATL ACAD SCI USA, V102, P8966, DOI 10.1073/pnas.0502678102
   Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912
   Messina E, 2004, CIRC RES, V95, P911, DOI 10.1161/01.RES.0000147315.71699.51
   Miyagawa S, 2002, CIRCULATION, V105, P2556, DOI 10.1161/01.CIR.0000016722.37138.F2
   Miyahara Y, 2006, NAT MED, V12, P459, DOI 10.1038/nm1391
   Nakamura T, 2000, J CLIN INVEST, V106, P1511, DOI 10.1172/JCI10226
   Passier R, 2008, NATURE, V453, P322, DOI 10.1038/nature07040
   Penn MS, 2008, CIRC RES, V102, P1471, DOI 10.1161/CIRCRESAHA.108.175174
   Rappolee DA, 1996, CIRC RES, V78, P1028, DOI 10.1161/01.RES.78.6.1028
   Rota M, 2008, CIRC RES, V103, P107, DOI 10.1161/CIRCRESAHA.108.178525
   Tang XL, 2010, CIRCULATION, V121, P293, DOI 10.1161/CIRCULATIONAHA.109.871905
   Tang YL, 2007, BIOCHEM BIOPH RES CO, V359, P877, DOI 10.1016/j.bbrc.2007.05.216
   Ueda H, 2001, CARDIOVASC RES, V51, P41, DOI 10.1016/S0008-6363(01)00272-3
   Urbanek K, 2005, CIRC RES, V97, P663, DOI 10.1161/01.RES.0000183733.53101.11
   van der Bogt KEA, 2008, CIRCULATION, V118, pS121, DOI 10.1161/CIRCULATIONAHA.107.759480
   Wang XH, 2006, STEM CELLS, V24, P1779, DOI 10.1634/stemcells.2005-0386
   Wang XH, 2009, CIRCULATION, V120, pS790
   Weber KT, 1997, CIRCULATION, V96, P2488
   Whelan RS, 2010, ANNU REV PHYSIOL, V72, P19, DOI 10.1146/annurev.physiol.010908.163111
   Zeng LP, 2007, CIRCULATION, V115, P1866, DOI 10.1161/CIRCULATIONAHA.106.659730
NR 36
TC 11
Z9 13
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 11
PY 2014
VL 9
IS 6
AR e95247
DI 10.1371/journal.pone.0095247
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AK7TQ
UT WOS:000338631000004
PM 24919180
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Jarajapu, YPR
   Hazra, S
   Segal, M
   LiCalzi, S
   Jhadao, C
   Qian, K
   Mitter, SK
   Raizada, MK
   Boulton, ME
   Grant, MB
AF Jarajapu, Yagna P. R.
   Hazra, Sugata
   Segal, Mark
   LiCalzi, Sergio
   Jhadao, Chandra
   Qian, Kevin
   Mitter, Sayak K.
   Raizada, Mohan K.
   Boulton, Michael E.
   Grant, Maria B.
TI Vasoreparative Dysfunction of CD34(+) Cells in Diabetic Individuals
   Involves Hypoxic Desensitization and Impaired Autocrine/Paracrine
   Mechanisms
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL PROGENITOR CELLS; GROWTH-FACTOR-BETA; CEREBRAL-ARTERIES;
   MYOCARDIAL-INFARCTION; CLONAL ANALYSIS; MYOGENIC TONE; NITRIC-OXIDE;
   STEM-CELLS; BLOOD-FLOW; ANGIOGENESIS
AB We hypothesized that endothelial progenitor cells derived from individuals with diabetes would exhibit functional defects including inability to respond to hypoxia and altered paracrine/autocrine function that would impair the angiogenic potential of these cells. Circulating mononuclear cells isolated from diabetic (n = 69) and nondiabetic (n = 46) individuals were used to grow endothelial colony forming cells (ECFC), early endothelial progenitor cells (eEPCs) and isolate CD34(+) cells. ECFCs and eEPCs were established from only 15% of the diabetic individuals tested thus directing our main effort toward examination of CD34(+) cells. CD34(+) cells were plated in basal medium to obtain cell-free conditioned medium (CM). In CM derived from CD34(+) cells of diabetic individuals (diabetic-CM), the levels of stem cell factor, hepatocyte growth factor, and thrombopoietin were lower, and IL-1 beta and tumor necrosis factor (TNF alpha) levels were higher than CM derived from nondiabetic individuals (nondiabetic-CM). Hypoxia did not upregulate HIF1 alpha in CD34(+) cells of diabetic origin. Migration and proliferation of nondiabetic CD34(+) cells toward diabetic-CM were lower compared to nondiabetic-CM. Attenuation of pressure-induced constriction, potentiation of bradykinin relaxation, and generation of cGMP and cAMP in arterioles were observed with nondiabetic-CM, but not with diabetic-CM. Diabetic-CM failed to induce endothelial tube formation from vascular tissue. These results suggest that diabetic subjects with microvascular complications exhibit severely limited capacity to generate ex-vivo expanded endothelial progenitor populations and that the vasoreparative dysfunction observed in diabetic CD34(+) cells is due to impaired autocrine/paracrine function and reduced sensitivity to hypoxia.
C1 [Jarajapu, Yagna P. R.] N Dakota State Univ, Coll Pharm Nursing & Allied Sci, Dept Pharmaceut Sci, Fargo, ND 58105 USA.
   [Jarajapu, Yagna P. R.; Hazra, Sugata; Jhadao, Chandra; Grant, Maria B.] Univ Florida, Coll Med, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA.
   [Segal, Mark] Univ Florida, Coll Med, Dept Nephrol, Gainesville, FL USA.
   [LiCalzi, Sergio; Qian, Kevin; Mitter, Sayak K.; Boulton, Michael E.; Grant, Maria B.] Indiana Univ, Sch Med, Dept Ophthalmol, Indianapolis, IN 46202 USA.
   [Raizada, Mohan K.] Univ Florida, Coll Med, Dept Physiol & Funct Genom, Gainesville, FL USA.
RP Grant, MB (reprint author), Univ Florida, Coll Med, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA.
EM mabgrant@iupui.edu
FU NIH [EY007739, EY012601, DK090730-02, U01HL087366, EY018358]
FX Funding Sources include NIH - EY007739, EY012601, DK090730-02, and
   U01HL087366 to MBG and EY018358 to MEB. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abdel-Wahab N, 2002, BIOCHEM J, V362, P643, DOI 10.1042/0264-6021:3620643
   Ali H, 1997, MED CLIN N AM, V81, P1, DOI 10.1016/S0025-7125(05)70503-4
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Awad O, 2006, ARTERIOSCL THROM VAS, V26, P758, DOI 10.1161/01.ATV.0000203513.29227.6f
   Barcelos LS, 2009, CIRC RES, V104, P1095, DOI 10.1161/CIRCRESAHA.108.192138
   Bhatwadekar AD, 2010, DIABETES, V59, P2010, DOI 10.2337/db10-0287
   Brizzi MF, 1999, CIRC RES, V84, P785
   Brock M, 2009, CIRC RES, V104, P1184, DOI 10.1161/CIRCRESAHA.109.197491
   Caballero S, 2007, DIABETES, V56, P960, DOI 10.2337/db06-1254
   Cai J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021164
   Dempsey RJ, 2003, J NEUROCHEM, V87, P586, DOI 10.1046/j.1471-4159.2003.02022.x
   Eguchi M, 2008, J MOL CELL CARDIOL, V45, P661, DOI 10.1016/j.yjmcc.2008.08.002
   Fadini GP, 2007, DIABETES CARE, V30, P1305, DOI 10.2337/dc06-2305
   Fadini GP, 2006, ARTERIOSCL THROM VAS, V26, P2140, DOI 10.1161/01.ATV.0000237750.44469.88
   Fadini GP, 2006, EUR HEART J, V27, P2247, DOI 10.1093/eurheartj/ehl198
   Fadini GP, 2009, ATHEROSCLEROSIS, V207, P213, DOI 10.1016/j.atherosclerosis.2009.03.040
   Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com
   Goldschmidt-Clermont Pascal J, 2005, Rev Cardiovasc Med, V6 Suppl 3, pS22
   Harraz M, 2001, STEM CELLS, V19, P304, DOI 10.1634/stemcells.19-4-304
   He T, 2008, CIRC RES, V103, P80, DOI 10.1161/CIRCRESAHA.108.176057
   He TR, 2005, AM J PHYSIOL-HEART C, V289, pH968, DOI 10.1152/ajpheart.01166.2004
   Jarajapu YPR, 2008, EUR J PHARMACOL, V579, P298, DOI 10.1016/j.ejphar.2007.10.028
   Jarajapu YPR, 2010, CIRC RES, V106, P854, DOI 10.1161/CIRCRESAHA.109.213140
   Jarajapu YP, 2011, INVEST OPHTH VIS SCI, V52, P5098
   Jarajapu YP, 2009, CIRC RES, V105, P897
   Jarajapu YPR, 2002, AM J PHYSIOL-HEART C, V283, pH2234, DOI 10.1152/ajpheart.00624.2002
   Jarajapu YPR, 2001, J PHARMACOL EXP THER, V299, P729
   JOHNSON PC, 1986, CIRC RES, V59, P483, DOI 10.1161/01.RES.59.5.483
   Juul A, 2002, CIRCULATION, V106, P939, DOI 10.1161/01.CIR.0000027563.44593.CC
   Katakam PVG, 2009, AM J PHYSIOL-REG I, V296, pR289, DOI 10.1152/ajpregu.90656.2008
   Krenning G, 2009, J CELL MOL MED, V13, P2521, DOI 10.1111/j.1582-4934.2008.00479.x
   Kristiansen OP, 2005, DIABETES, V54, pS114, DOI 10.2337/diabetes.54.suppl_2.S114
   Loomans CJM, 2004, DIABETES, V53, P195, DOI 10.2337/diabetes.53.1.195
   Losordo DW, 2007, CIRCULATION, V115, P3165, DOI 10.1161/CIRCULATIONAHA.106.687376
   Mackie AR, 2011, TEX HEART I J, V38, P474
   Majka M, 2001, BLOOD, V97, P3075, DOI 10.1182/blood.V97.10.3075
   Martin-Ramirez J, 2012, NAT PROTOC, V7, P1709, DOI 10.1038/nprot.2012.093
   Meng S, 2012, J MOL CELL CARDIOL, V53, P64, DOI 10.1016/j.yjmcc.2012.04.003
   Milkiewicz M, 2004, J PHYSIOL-LONDON, V560, P21, DOI 10.1113/jphysiol.2004.069757
   Mirotsou M, 2007, P NATL ACAD SCI USA, V104, P1643, DOI 10.1073/pnas.0610024104
   Mohty M, 2011, EXP HEMATOL
   Mukai N, 2008, EXP CELL RES, V314, P430, DOI 10.1016/j.yexcr.2007.11.016
   Nakagawa T, 2006, J AM SOC NEPHROL, V17, P736, DOI 10.1681/ASN.2005070759
   Narazaki M, 2006, BLOOD, V107, P3892, DOI 10.1182/blood-2005-10-4113
   Orlandi A, 2010, BASIC RES CARDIOL, V105, P703, DOI 10.1007/s00395-010-0109-0
   Ramos AL, 2010, CIRC RES, V107, P1460, DOI 10.1161/CIRCRESAHA.110.223669
   Raval Z, 2013, CIRC RES, V112, P1288, DOI 10.1161/CIRCRESAHA.113.300565
   Romero MJ, 2008, CIRC RES, V102, P95, DOI 10.1161/CIRCRESAHA.107.155028
   Ronnstrand L, 2004, CELL MOL LIFE SCI, V61, P2535, DOI 10.1007/s00018-004-4189-6
   Santos SCR, 2007, EXP CELL RES, V313, P1561, DOI 10.1016/j.yexcr.2007.02.020
   Santhanam AVR, 2007, CIRC RES, V100, P1379, DOI 10.1161/01.RES.0000265848.55035.5d
   Schatteman GC, 2000, J CLIN INVEST, V106, P571, DOI 10.1172/JCI9087
   Schatteman GC, 2010, AM J PATHOL, V177, P2002, DOI 10.2353/ajpath.2010.091232
   Schroder K, 2010, ANTIOXID REDOX SIGNA
   Segal MS, 2006, DIABETES, V55, P102, DOI 10.2337/diabetes.55.1.102
   Sekiguchi H, 2009, J CELL PHYSIOL, V219, P235, DOI 10.1002/jcp.21672
   Semenza GL, 1999, ANN NY ACAD SCI, V874, P262, DOI 10.1111/j.1749-6632.1999.tb09241.x
   Sieveking DP, 2008, J AM COLL CARDIOL, V51, P660, DOI 10.1016/j.jacc.2007.09.059
   Smith G, 1999, BRIT J OPHTHALMOL, V83, P486, DOI 10.1136/bjo.83.4.486
   Tan K, 2010, EXP EYE RES, V91, P229, DOI 10.1016/j.exer.2010.05.012
   Tang YL, 2009, CIRC RES, V104, P1209, DOI 10.1161/CIRCRESAHA.109.197723
   Tepper OM, 2002, CIRCULATION, V106, P2781, DOI 10.1161/01.CIR.0000039526.42991.93
   Ulyatt C, 2011, BIOCHEM BIOPH RES CO, V404, P774, DOI 10.1016/j.bbrc.2010.12.057
   YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0
   Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471
   Yoon CH, 2005, CIRCULATION, V112, P1618, DOI 10.1161/CIRCULATIONAHA.104.503433
   Zhu GX, 2010, INT J CARDIOL, V138, P70, DOI 10.1016/j.ijcard.2008.10.042
NR 67
TC 20
Z9 21
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 8
PY 2014
VL 9
IS 4
AR e93965
DI 10.1371/journal.pone.0093965
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AE7FA
UT WOS:000334160900068
PM 24713821
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Yu, B
   Gong, M
   Wang, YG
   Millard, RW
   Pasha, Z
   Yang, YT
   Ashraf, M
   Xu, MF
AF Yu, Bin
   Gong, Min
   Wang, Yigang
   Millard, Ronald W.
   Pasha, Zeeshan
   Yang, Yueting
   Ashraf, Muhammad
   Xu, Meifeng
TI Cardiomyocyte Protection by GATA-4 Gene Engineered Mesenchymal Stem
   Cells Is Partially Mediated by Translocation of miR-221 in Microvesicles
SO PLOS ONE
LA English
DT Article
ID ACUTE MYOCARDIAL-INFARCTION; ISCHEMIC-HEART; SURVIVAL; THERAPY; BCL-2;
   BAX; TRANSPLANTATION; MICRORNAS; MECHANISM; APOPTOSIS
AB Introduction: microRNAs (miRs), a novel class of small non-coding RNAs, are involved in cell proliferation, differentiation, development, and death. In this study, we found that miR-221 translocation by microvesicles (MVs) plays an important role in cardioprotection mediated by GATA-4 overexpressed mesenchymal stem cells (MSC).
   Methods and Results: Adult rat bone marrow MSC and neonatal rat ventricle cardiomyocytes (CM) were harvested as primary cultures. MSC were transduced with GATA-4 (MSCGATA-4) using the murine stem cell virus (pMSCV) retroviral expression system. Empty vector transfection was used as a control (MSCNull). The expression of miRs was assessed by real-time PCR and localized using in situ hybridization (ISH). MVs collected from MSC cultures were characterized by expression of CD9, CD63, and HSP70, and photographed with electron microscopy. Cardioprotection during hypoxia afforded by conditioned medium (CdM) from MSC cultures was evaluated by lactate dehydrogenase (LDH) release, MTS uptake by CM, and caspase 3/7 activity. Expression of miR-221/222 was significantly higher in MSC than in CM and miR-221 was upregulated in MSCGATA-4. MSC overexpression of miR-221 significantly enhanced cardioprotection by reducing the expression of p53 upregulated modulator of apoptosis (PUMA). Moreover, expression of PUMA was significantly decreased in CM co-cultured with MSC. MVs derived from MSC expressed high levels of miR-221, and were internalized quickly by CM as documented in images obtained from a Time-Lapse Imaging System.
   Conclusions: Our results demonstrate that cardioprotection by MSCGATA-4 may be regulated in part by a transfer of antiapoptotic miRs contained within MVs.
C1 [Yu, Bin; Gong, Min; Wang, Yigang; Pasha, Zeeshan; Yang, Yueting; Ashraf, Muhammad; Xu, Meifeng] Univ Cincinnati, Med Ctr, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA.
   [Millard, Ronald W.] Univ Cincinnati, Med Ctr, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA.
RP Xu, MF (reprint author), Univ Cincinnati, Med Ctr, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA.
EM meifeng.xu@uc.edu
FU National Institutes of Health [HL105176, HL114654]
FX This work was supported by National Institutes of Health grants HL105176
   and HL114654 (to M. Xu). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Angoulvant D, 2011, J HEART LUNG TRANSPL, V30, P95, DOI 10.1016/j.healun.2010.08.023
   Assmus B, 2010, CIRC-HEART FAIL, V3, P89, DOI 10.1161/CIRCHEARTFAILURE.108.843243
   Biancone L, 2012, NEPHROL DIAL TRANSPL, V27, P3037, DOI 10.1093/ndt/gfs168
   Boomsma RA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035685
   Boonbaichaiyapruck Sarana, 2010, Clin Cardiol, V33, pE10, DOI 10.1002/clc.20545
   Burchfield JS, 2008, FIBROGENESIS TISSUE, V1, DOI 10.1186/1755-1536-1-4
   Camussi G, 2013, BIOCHEM SOC T, V41, P283, DOI 10.1042/BST20120192
   Chen L, 2013, BIOCH BIOPHYS RES CO
   Follis AV, 2013, NAT CHEM BIOL
   Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826
   Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com
   Jabbour AM, 2009, CELL DEATH DIFFER, V16, P555, DOI 10.1038/cdd.2008.179
   Kajstura J, 2005, CIRC RES, V96, P127, DOI 10.1161/01.RES.0000151843.79801.60
   Lai RC, 2011, REGEN MED, V6, P481, DOI [10.2217/rme.11.35, 10.2217/RME.11.35]
   Leri Annarosa, 2007, Drug Discov Today Dis Mech, V4, P197, DOI 10.1016/j.ddmec.2008.02.008
   Li HX, 2010, AM J PHYSIOL-HEART C, V299, pH1772, DOI 10.1152/ajpheart.00557.2010
   Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2
   Meyer GP, 2009, EUR HEART J, V30, P2978, DOI 10.1093/eurheartj/ehp374
   Nguyen BK, 2010, J CARDIOVASC TRANSL, V3, P547, DOI 10.1007/s12265-010-9171-0
   Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587
   Poynter JA, 2011, J AM COLL SURGEONS, V213, P253, DOI 10.1016/j.jamcollsurg.2011.04.005
   Quevedo HC, 2009, P NATL ACAD SCI USA, V106, P14022, DOI 10.1073/pnas.0903201106
   Rota M, 2007, P NATL ACAD SCI USA, V104, P17783, DOI 10.1073/pnas.0706406104
   Sadat S, 2007, BIOCHEM BIOPH RES CO, V363, P674, DOI 10.1016/j.bbrc.2007.09.058
   Sharma AD, 2011, HEPATOLOGY, V53, P1651, DOI 10.1002/hep.24243
   Tongers J, 2011, EUR HEART J, V32, P1197, DOI 10.1093/eurheartj/ehr018
   Uemura R, 2006, CIRC RES, V98, P1414, DOI 10.1161/01.RES.0000225952.61196.39
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0
   Villunger A, 2003, BLOOD, V101, P2393, DOI 10.1182/blood-2002-07-2132
   Wollert KC, 2004, LANCET, V364, P141, DOI 10.1016/S0140-6736(04)16626-9
   Xu MF, 2004, CIRCULATION, V110, P2658, DOI 10.1161/01.CIR.0000145609.20435.36
   Yousef M, 2009, J AM COLL CARDIOL, V53, P2262, DOI 10.1016/j.jacc.2009.02.051
   Yuan A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004722
   Zeng LP, 2007, CIRCULATION, V115, P1866, DOI 10.1161/CIRCULATIONAHA.106.659730
   Zhang CZ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-229
   Zhang XW, 2010, J MOL CELL CARDIOL, V49, P841, DOI 10.1016/j.yjmcc.2010.08.007
NR 37
TC 47
Z9 60
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 28
PY 2013
VL 8
IS 8
AR e73304
DI 10.1371/journal.pone.0073304
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 209DG
UT WOS:000323733800097
PM 24015301
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Cai, BZ
   Li, XD
   Wang, Y
   Liu, YJ
   Yang, F
   Chen, HY
   Yin, K
   Tan, XY
   Zhu, JX
   Pan, ZW
   Wang, BQ
   Lu, YJ
AF Cai, Benzhi
   Li, Xingda
   Wang, Yang
   Liu, Yanju
   Yang, Fan
   Chen, Hongyang
   Yin, Kun
   Tan, Xueying
   Zhu, Jiuxin
   Pan, Zhenwei
   Wang, Baoqiu
   Lu, Yanjie
TI Apoptosis of Bone Marrow Mesenchymal Stem Cells Caused by Homocysteine
   via Activating JNK Signal
SO PLOS ONE
LA English
DT Article
ID OXIDATIVE STRESS; REACTIVE OXYGEN; ISCHEMIC-HEART; GROWTH; DEATH;
   DIFFERENTIATION; SURVIVAL; DISEASE; ATHEROSCLEROSIS; EXPRESSION
AB Bone marrow mesenchymal stem cells (BMSCs) are capable of homing to and repair damaged myocardial tissues. Apoptosis of BMSCs in response to various pathological stimuli leads to the attenuation of healing ability of BMSCs. Plenty of evidence has shown that elevated homocysteine level is a novel independent risk factor of cardiovascular diseases. The present study was aimed to investigate whether homocysteine may induce apoptosis of BMSCs and its underlying mechanisms. Here we uncovered that homocysteine significantly inhibited the cellular viability of BMSCs. Furthermore, TUNEL, AO/EB, Hoechst 333342 and Live/Death staining demonstrated the apoptotic morphological appearance of BMSCs after homocysteine treatment. A distinct increase of ROS level was also observed in homocysteine-treated BMSCs. The blockage of ROS by DMTU and NAC prevented the apoptosis of BMSCs induced by homocysteine, indicating ROS was involved in the apoptosis of BMSCs. Moreover, homocysteine also caused the depolarization of mitochondrial membrane potential of BMSCs. Furthermore, apoptotic appearance and mitochondrial membrane potential depolarization in homocysteine-treated BMSCs was significantly reversed by JNK inhibitor but not p38 MAPK and ERK inhibitors. Western blot also confirmed that p-JNK was significantly activated after exposing BMSCs to homocysteine. Homocysteine treatment caused a significant reduction of BMSCs-secreted VEGF and IGF-1 in the culture medium. Collectively, elevated homocysteine induced the apoptosis of BMSCs via ROS-induced the activation of JNK signal, which provides more insight into the molecular mechanisms of hyperhomocysteinemia-related cardiovascular diseases.
C1 [Cai, Benzhi; Li, Xingda; Wang, Yang; Liu, Yanju; Yang, Fan; Chen, Hongyang; Yin, Kun; Tan, Xueying; Zhu, Jiuxin; Pan, Zhenwei; Wang, Baoqiu; Lu, Yanjie] Harbin Med Univ, Dept Pharmacol, State Prov Key Labs Biomed Pharmaceut China, Harbin, Heilongjiang Pr, Peoples R China.
   [Lu, Yanjie] Harbin Med Univ, Inst Cardiovasc Res, Harbin, Heilongjiang Pr, Peoples R China.
RP Lu, YJ (reprint author), Harbin Med Univ, Dept Pharmacol, State Prov Key Labs Biomed Pharmaceut China, Harbin, Heilongjiang Pr, Peoples R China.
EM Yjlu86@yahoo.com
FU Funds for Creative Research Groups of The National Natural Science
   Foundation of China [81121003]; National Natural Science Fund of China
   [81170096]; Program for New Century Excellent Talents In Heilongjiang
   Provincial University [1155-NCET-010]
FX This work was supported by the Funds for Creative Research Groups of The
   National Natural Science Foundation of China (81121003), the National
   Natural Science Fund of China (81170096) and the Program for New Century
   Excellent Talents In Heilongjiang Provincial University (1155-NCET-010).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Anker PSI, 2003, HAEMATOLOGICA, V88, P845
   Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001
   Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002
   Cai BZ, 2007, CLIN EXP PHARMACOL P, V34, P851, DOI 10.1111/j.1440-1681.2007.04671.x
   Cai BZ, 2007, LIFE SCI, V80, P2060, DOI 10.1016/j.lfs.2007.03.003
   Cai BZ, 2012, STEM CELLS, V30, P1746, DOI [10.1002/stem.01154, 10.1002/stem.1154]
   Cai BZ, 2011, INT J CARDIOL, V150, P113, DOI 10.1016/j.ijcard.2011.04.031
   Cai BZ, 2009, J MOL CELL CARDIOL, V47, P41, DOI 10.1016/j.yjmcc.2009.03.002
   Cai BZ, 2009, TOXICOLOGY, V256, P201, DOI 10.1016/j.tox.2008.11.020
   Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6
   Chang PY, 2008, CIRC RES, V102, P933, DOI 10.1161/CIRCRESAHA.108.171082
   Chavarria T, 2003, BIOCHEM BIOPH RES CO, V303, P572, DOI 10.1016/S0006-291X(03)00382-6
   Crisostomo PR, 2008, AM J PHYSIOL-CELL PH, V294, pC675, DOI 10.1152/ajpcell.00437.2007
   Danese S, 2005, AM J GASTROENTEROL, V100, P886, DOI 10.1111/j.1572-0241.2005.41469.x
   Falk E, 2001, LIPIDS, V36, pS3, DOI 10.1007/s11745-001-0676-x
   Gnecchi M, 2005, NAT MED, V11, P367, DOI 10.1038/nm0405-367
   Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com
   Guthikonda S, 1999, CURR OPIN CARDIOL, V14, P283, DOI 10.1097/00001573-199907000-00002
   Kang YH, 2008, J CELL PHYSIOL, V217, P23, DOI 10.1002/jcp.21470
   Kim HW, 2009, J BIOL CHEM, V284, P33161, DOI 10.1074/jbc.M109.020925
   Kim HJ, 2006, ONCOGENE, V25, P2785, DOI 10.1038/sj.onc.1209303
   Korbling M, 2003, NEW ENGL J MED, V349, P570, DOI 10.1056/NEJMra022361
   Kortesidis A, 2005, BLOOD, V105, P3793, DOI 10.1182/blood-2004-11-4349
   Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0
   Levrand S, 2007, BIOCHEM BIOPH RES CO, V359, P445, DOI 10.1016/j.bbrc.2007.05.147
   Li JX, 2010, MOL BIOL REP, V37, P1569, DOI 10.1007/s11033-009-9561-z
   Ponte AL, 2007, STEM CELLS, V25, P1737, DOI 10.1634/stemcells.2007-0054
   Majumdar MK, 2000, J HEMATOTH STEM CELL, V9, P841, DOI 10.1089/152581600750062264
   Malinowska Joanna, 2009, Pol Merkur Lekarski, V27, P413
   Noiseux N, 2006, MOL THER, V14, P840, DOI 10.1016/j.ymthe.2006.05.016
   Papa S, 1997, MOL CELL BIOCHEM, V174, P305, DOI 10.1023/A:1006873518427
   Shen HM, 2006, FREE RADICAL BIO MED, V40, P928, DOI 10.1016/j.freeradbiomed.2005.10.056
   Silva GV, 2005, CIRCULATION, V111, P150, DOI 10.1161/01.CIR.0000151812.86142.45
   Sipkens JA, 2007, APOPTOSIS, V12, P1407, DOI 10.1007/s10495-007-0077-5
   Stamm C, 2006, CELL TRANSPLANT, V15, pS47
   Suhara T, 2004, HYPERTENSION, V43, P1208, DOI 10.1161/01.HYP.0000127914.94292.76
   Tang YL, 2005, ANN THORAC SURG, V80, P229, DOI 10.1016/j.athoracsur.2005.02.072
   Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442
   TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369
   Wald DS, 2002, BRIT MED J, V325, P1202, DOI 10.1136/bmj.325.7374.1202
   Wisel S, 2009, J PHARMACOL EXP THER, V329, P543, DOI 10.1124/jpet.109.150839
   Yang YJ, 2008, EUR HEART J, V29, P1578, DOI 10.1093/eurheartj/ehn167
   Zhang C, 2001, J BIOL CHEM, V276, P35867, DOI 10.1074/jbc.M100747200
NR 43
TC 19
Z9 22
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 7
PY 2013
VL 8
IS 5
AR e63561
DI 10.1371/journal.pone.0063561
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 154EP
UT WOS:000319654700161
PM 23667638
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Yang, DZ
   Wang, W
   Li, LP
   Peng, YL
   Chen, P
   Huang, HY
   Guo, YL
   Xia, XW
   Wang, YY
   Wang, HY
   Wang, WE
   Zeng, CY
AF Yang, Dezhong
   Wang, Wei
   Li, Liangpeng
   Peng, Yulan
   Chen, Peng
   Huang, Haiyun
   Guo, Yanli
   Xia, Xuewei
   Wang, Yuanyuan
   Wang, Hongyong
   Wang, Wei Eric
   Zeng, Chunyu
TI The Relative Contribution of Paracine Effect versus Direct
   Differentiation on Adipose-Derived Stem Cell Transplantation Mediated
   Cardiac Repair
SO PLOS ONE
LA English
DT Article
ID ACUTE MYOCARDIAL-INFARCTION; FUNCTIONAL IMPROVEMENT; REGENERATIVE
   MEDICINE; PARACRINE MECHANISMS; CONDITIONED MEDIUM; STROMAL CELLS;
   IN-VITRO; HEART; THERAPY; DISEASE
AB Background: Recent studies have demonstrated that transplantation of adipose-derived stem cell (ADSC) can improve cardiac function in animal models of myocardial infarction (MI). However, the mechanisms underlying the beneficial effect are not fully understood. In this study, we characterized the paracrine effect of transplanted ADSC and investigated its relative importance versus direct differentiation in ADSC transplantation mediated cardiac repair.
   Methodology/Principal Findings: MI was experimentally induced in mice by ligation of the left anterior descending coronary artery. Either human ADSC, conditioned medium (CM) collected from the same amount of ADSC or control medium was injected into the peri-infarct region immediately after MI. Compared with the control group, both ADSC and ADSC-CM significantly reduced myocardial infarct size and improved cardiac function. The therapeutic efficacy of ADSC was moderately superior to ADSC-CM. ADSC-CM significantly reduced cardiomyocyte apoptosis in the infarct border zone, to a similar degree with ADSC treatment. ADSC enhanced angiogenesis in the infarct border zone, but to a stronger degree than that seen in the ADSC-CM treatment. ADSC was able to differentiate to endothelial cell and smooth muscle cell in post-MI heart; these ADSC-derived vascular cells amount to about 9% of the enhanced angiogenesis. No cardiomyocyte differentiated from ADSC was found.
   Conclusions: ADSC-CM is sufficient to improve cardiac function of infarcted hearts. The therapeutic function of ADSC transplantation is mainly induced by paracrine-mediated cardioprotection and angiogenesis, while ADSC differentiation contributes a minor benefit by being involved in angiogenesis. Highlights 1 ADSC-CM is sufficient to exert a therapeutic potential. 2. ADSC was able to differentiate to vascular cells but not cardiomyocyte. 3. ADSC derived vascular cells amount to about 9% of the enhanced angiogenesis. 4. Paracrine effect is the major mechanism of ADSC therapeutic function for MI.
C1 [Yang, Dezhong; Wang, Wei; Li, Liangpeng; Peng, Yulan; Chen, Peng; Xia, Xuewei; Wang, Hongyong; Wang, Wei Eric; Zeng, Chunyu] Third Mil Med Univ, Daping Hosp, Dept Cardiol, Chongqing, Peoples R China.
   [Huang, Haiyun; Guo, Yanli] Third Mil Med Univ, Southwest Hosp, Dept Ultrasonog, Chongqing, Peoples R China.
   [Wang, Yuanyuan] Third Mil Med Univ, Daping Hosp, Dept Plast Surg, Chongqing, Peoples R China.
RP Wang, WE (reprint author), Third Mil Med Univ, Daping Hosp, Dept Cardiol, Chongqing, Peoples R China.
EM wangw28@gmail.com; cyzeng1@hotmail.com
OI Murtaugh, Maureen/0000-0001-5281-0302
FU National Natural Science Foundation of China [31130029, 81100111,
   30925018]; Natural Science Foundation Project of CQ CSTC (CSTC)
   [2009BA5044]; National Basic Research Program of China (973 Program)
   [2008CB517308, 2012CB517801]
FX This study was supported by the grants from the National Natural Science
   Foundation of China (31130029, 81100111, 30925018), Natural Science
   Foundation Project of CQ CSTC (CSTC, 2009BA5044), and National Basic
   Research Program of China (973 Program, 2008CB517308, 2012CB517801). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Bai XW, 2010, EUR HEART J, V31, P489, DOI 10.1093/eurheartj/ehp568
   Bayes-Genis A, 2010, J MOL CELL CARDIOL, V49, P771, DOI 10.1016/j.yjmcc.2010.08.010
   Bergmann O, 2009, SCIENCE, V324, P98, DOI 10.1126/science.1164680
   Biancone L, 2012, NEPHROL DIAL TRANSPL, V27, P3037, DOI 10.1093/ndt/gfs168
   Chacko SM, 2010, AM J PHYSIOL-CELL PH, V299, pC1562, DOI 10.1152/ajpcell.00221.2010
   Chimenti I, 2010, CIRC RES, V106, P971, DOI 10.1161/CIRCRESAHA.109.210682
   Cho YJ, 2012, J NEUROSCI RES, V90, P1794, DOI 10.1002/jnr.23063
   Christoffels V, 2011, NATURE, V474, P585, DOI 10.1038/474585a
   Crow MT, 2004, CIRC RES, V95, P957, DOI 10.1161/01.RES.0000148632.35500.d9
   Deuse T, 2009, CIRCULATION, V120, pS247, DOI 10.1161/CIRCULATIONAHA.108.843680
   Deveza L, 2013, STEM CELLS DEV, V22, P483, DOI 10.1089/scd.2012.0201
   Egashira Y, 2012, BRAIN RES, V1461, P87, DOI 10.1016/j.brainres.2012.04.033
   Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826
   Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com
   Kubo H, 2008, CIRCULATION, V118, P649, DOI 10.1161/CIRCULATIONAHA.107.761031
   Li TS, 2012, J AM COLL CARDIOL, V59, P942, DOI 10.1016/j.jacc.2011.11.029
   Li XH, 2007, J MOL CELL CARDIOL, V42, P295, DOI 10.1016/j.yjmcc.2006.07.002
   Li YX, 2011, CIRCULATION, V123, P866, DOI 10.1161/CIRCULATIONAHA.110.947531
   Madonna R, 2009, ARTERIOSCL THROM VAS, V29, P1723, DOI 10.1161/ATVBAHA.109.187179
   Mazo M, 2008, EUR J HEART FAIL, V10, P454, DOI 10.1016/j.ejheart.2008.03.017
   Miranville A, 2004, CIRCULATION, V110, P349, DOI 10.1161/01.CIR.0000135466.16823.D0
   Mirotsou M, 2011, J MOL CELL CARDIOL, V50, P280, DOI 10.1016/j.yjmcc.2010.08.005
   Planat-Benard V, 2004, CIRCULATION, V109, P656, DOI 10.1161/01.CIR.0000114522.38265.61
   Planat-Benard V, 2004, CIRC RES, V94, P223, DOI 10.1161/01.RES.0000109792.43271.47
   Ramkisoensing AA, 2012, STEM CELLS, V30, P1236, DOI 10.1002/stem.1086
   Ratajczak MZ, 2012, LEUKEMIA, V26, P1166, DOI 10.1038/leu.2011.389
   Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1
   Sanchez PL, 2010, EUR HEART J, V31, P394, DOI 10.1093/eurheartj/ehp403
   Segers VFM, 2008, NATURE, V451, P937, DOI 10.1038/nature06800
   Son NH, 2010, J CLIN INVEST, V120, P3443, DOI 10.1172/JCI40905
   Tang JM, 2011, CARDIOVASC RES, V91, P402, DOI 10.1093/cvr/cvr053
   Tongers J, 2011, EUR HEART J, V32, P1197, DOI 10.1093/eurheartj/ehr018
   Valina C, 2007, EUR HEART J, V28, P2667, DOI 10.1093/eurheartj/ehm426
   van Poll D, 2008, HEPATOLOGY, V47, P1634, DOI 10.1002/hep.22236
   Wang L, 2009, AM J PHYSIOL-HEART C, V297, pH1020, DOI 10.1152/ajpheart.01082.2008
   Wang XH, 2009, CIRCULATION, V120, pS238, DOI 10.1161/CIRCULATIONAHA.109.885236
   Williams AR, 2011, CIRC RES, V109, P923, DOI 10.1161/CIRCRESAHA.111.243147
   Xiong DZ, 2010, J MOL CELL CARDIOL, V48, P211, DOI 10.1016/j.yjmcc.2009.07.003
   Yang JJ, 2012, TOHOKU J EXP MED, V226, P231, DOI 10.1620/tjem.226.231
   Zhang HY, 2010, CIRC RES, V107, P800, DOI 10.1161/CIRCRESAHA.110.219220
NR 40
TC 135
Z9 141
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 19
PY 2013
VL 8
IS 3
AR e59020
DI 10.1371/journal.pone.0059020
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 125SR
UT WOS:000317562100066
PM 23408942
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Chang, YS
   Choi, SJ
   Ahn, SY
   Sung, DK
   Sung, SI
   Yoo, HS
   Oh, WI
   Park, WS
AF Chang, Yun Sil
   Choi, Soo Jin
   Ahn, So Yoon
   Sung, Dong Kyung
   Sung, Se In
   Yoo, Hye Soo
   Oh, Won Il
   Park, Won Soon
TI Timing of Umbilical Cord Blood Derived Mesenchymal Stem Cells
   Transplantation Determines Therapeutic Efficacy in the Neonatal
   Hyperoxic Lung Injury
SO PLOS ONE
LA English
DT Article
ID NADPH OXIDASE COMPLEX; ENDOTHELIAL-CELLS; RETINOIC ACID; MICE; GROWTH;
   ALVEOLARIZATION; INFANTS; BIRTH; RATS
AB Intratracheal transplantation of human umbilical cord blood (UCB)-derived mesenchymal stem cells (MSCs) attenuates the hyperoxia-induced neonatal lung injury. The aim of this study was to optimize the timing of MSCs transplantation. Newborn Sprague-Dawley rats were randomly exposed to hyperoxia (90% for 2 weeks and 60% for 1 week) or normoxia after birth for 21 days. Human UCB-derived MSCs (5x10(5) cells) were delivered intratracheally early at postnatal day (P) 3 (HT3), late at P10 (HT10) or combined early+late at P3+10 (HT3+10). Hyperoxia-induced increase in mortality, TUNEL positive cells, ED1 positive alveolar macrophages, myeloperoxidase activity and collagen levels, retarded growth and reduced alveolarization as evidenced by increased mean linear intercept and mean alveolar volume were significantly better attenuated in both HT3 and HT3+10 than in HT10. Hyperoxia-induced up-regulation of both cytosolic and membrane p47(phox) indicative of oxidative stress, and increased inflammatory markers such as tumor necrosis factor-alpha, interleukin (IL)-1 alpha, IL-1 beta, IL-6, and transforming growth factor-beta measured by ELISA, and tissue inhibitor of metalloproteinase-1, CXCL7, RANTES, L-selectin and soluble intercellular adhesion molecule-1 measured by protein array were consistently more attenuated in both HT3 and HT3+10 than in HT10. Hyperoxia-induced decrease in hepatocyte growth factor and vascular endothelial growth factor was significantly up-regulated in both HT3 and HT3+10, but not in HT10. In summary, intratracheal transplantation of human UCB derived MSCs time-dependently attenuated hyperoxia-induced lung injury in neonatal rats, showing significant protection only in the early but not in the late phase of inflammation. There were no synergies with combined early+late MSCs transplantation.
C1 [Chang, Yun Sil; Ahn, So Yoon; Sung, Se In; Yoo, Hye Soo; Park, Won Soon] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pediat, Seoul, South Korea.
   [Chang, Yun Sil; Sung, Dong Kyung; Park, Won Soon] Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Seoul, South Korea.
   [Choi, Soo Jin; Oh, Won Il] MEDIPOST Co Ltd, Biomed Res Inst, Seoul, South Korea.
RP Park, WS (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pediat, Seoul, South Korea.
EM wonspark@skku.edu
FU Ministry for Health, Welfare & Family Affairs, Republic of Korea
   [A102136]; National Research Foundation of Korea (NRF); Ministry of
   Education, Science, and Technology [S-2011-0317-000]; Samsung Biomedical
   Research Institute Grant [SBRI CB11271]
FX This work was supported by a grant from the Korea Healthcare technology
   R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of
   Korea (A102136), by the Basic Science Research Program through the
   National Research Foundation of Korea (NRF) funded by the Ministry of
   Education, Science, and Technology (S-2011-0317-000), and by a Samsung
   Biomedical Research Institute Grant (#SBRI CB11271). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Aslam M, 2009, AM J RESP CRIT CARE, V180, P1122, DOI 10.1164/rccm.200902-0242OC
   AVERY ME, 1987, PEDIATRICS, V79, P26
   Babior BM, 1999, BLOOD, V93, P1464
   BASTIAN NR, 1994, CURR OPIN IMMUNOL, V6, P131, DOI 10.1016/0952-7915(94)90044-2
   Boiani M, 2005, NAT REV MOL CELL BIO, V6, P872, DOI 10.1038/nrm1744
   BREGMAN J, 1992, CLIN PERINATOL, V19, P673
   Chang YL, 2011, CELL TRANSPLANT
   Chang YS, 2009, CELL TRANSPLANT, V18, P869, DOI 10.3727/096368909X471189
   Cho HJ, 2007, J EXP MED, V204, P3257, DOI 10.1084/jem.20070166
   Cho SJ, 2005, AM J RESP CELL MOL, V33, P622, DOI 10.1165/rcmb.2005-0050OC
   Choo-Wing R, 2007, AM J PHYSIOL-LUNG C, V293, pL142, DOI 10.1152/ajplung.00434.2006
   Coalson Jacqueline J, 2003, Semin Neonatol, V8, P73, DOI 10.1016/S1084-2756(02)00193-8
   Cross AR, 2004, BBA-BIOENERGETICS, V1657, P1, DOI 10.1016/j.bbabio.2004.03.008
   Deuse T, 2009, CIRCULATION, V120, pS247, DOI 10.1161/CIRCULATIONAHA.108.843680
   Fahy John V, 2009, Proc Am Thorac Soc, V6, P256, DOI 10.1513/pats.200808-087RM
   Gang EJ, 2007, BLOOD, V109, P1743, DOI 10.1182/blood-2005-11-010504
   Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com
   Gray KD, 2003, AM J SURG, V186, P526, DOI 10.1016/j.amjsurg.2003.07.010
   Hohler B, 2000, HISTOCHEM CELL BIOL, V114, P29
   Jang YK, 2006, ANN HEMATOL, V85, P212, DOI 10.1007/s00277-005-0047-3
   Jobe AJ, 1999, PEDIATR RES, V46, P641, DOI 10.1203/00006450-199912000-00001
   Kokaia Z, 2012, NAT NEUROSCI, V5, P1078
   Kunig AM, 2005, AM J PHYSIOL-LUNG C, V289, pL529, DOI 10.1152/ajplung.00336.2004
   Lee JK, 2007, CELL TRANSPLANT, V16, P849, DOI 10.3727/000000007783465271
   Li JM, 2002, J BIOL CHEM, V277, P19952, DOI 10.1074/jbc.M110073200
   McGrath-Morrow SA, 2001, AM J RESP CELL MOL, V25, P150, DOI 10.1165/ajrcmb.25.2.4362
   Moodley Y, 2009, AM J PATHOL, V175, P303, DOI 10.2353/ajpath.2009.080629
   Reinecke H, 2002, J MOL CELL CARDIOL, V34, P251, DOI 10.1006/jmcc.2001.1494
   ROBINSON JM, 1995, HISTOCHEM CELL BIOL, V103, P163, DOI 10.1007/BF01454021
   Saigal S, 2008, LANCET, V371, P261, DOI 10.1016/S0140-6736(08)60136-1
   Saugstad Ola Didrik, 2003, Semin Neonatol, V8, P39, DOI 10.1016/S1084-2756(02)00194-X
   Snyder JM, 2005, PEDIATR RES, V57, P384, DOI 10.1203/01.PDR.0000151315.81106.D3
   THURLBECK WM, 1982, THORAX, V37, P564, DOI 10.1136/thx.37.8.564
   Togel F, 2005, AM J PHYSIOL-RENAL, V289, pF31, DOI 10.1152/ajprenal.00007.2005
   Warner BB, 1998, AM J PHYSIOL-LUNG C, V275, pL110, DOI 10.1152/ajplung.1998.275.1.L110
   Yang SE, 2004, CYTOTHERAPY, V6, P476, DOI 10.1080/14653240410005041
NR 36
TC 113
Z9 117
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 21
PY 2013
VL 8
IS 1
AR e52419
DI 10.1371/journal.pone.0052419
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 076FX
UT WOS:000313943000008
PM 23349686
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Jin, JL
   Zhao, YM
   Tan, X
   Guo, C
   Yang, ZJ
   Miao, DS
AF Jin, Jianliang
   Zhao, Yingming
   Tan, Xiao
   Guo, Chun
   Yang, Zhijian
   Miao, Dengshun
TI An Improved Transplantation Strategy for Mouse Mesenchymal Stem Cells in
   an Acute Myocardial Infarction Model
SO PLOS ONE
LA English
DT Article
ID BONE-MARROW; INDUCED APOPTOSIS; PROGENITOR CELLS; REGENERATION;
   DIFFERENTIATION; HEART; AKT; ANGIOGENESIS; CONTRIBUTES; ACTIVATION
AB To develop an effective therapeutic strategy for cardiac regeneration using bone marrow mesenchymal stem cells (BM-MSCs), the primary mouse BM-MSCs (1(st) BM-MSCs) and 5(th) passage BM-MSCs from beta-galactosidase transgenic mice were respectively intramyocardially transplanted into the acute myocardial infarction (AMI) model of wild type mice. At the 6(th) week, animals/tissues from the 1(st) BM-MSCs group, the 5(th) passage BM-MSCs group, control group were examined. Our results revealed that, compared to the 5(th) passage BM-MSCs, the 1(st) BM-MSCs had better therapeutic effects in the mouse MI model. The 1 st BM-MSCs maintained greater differentiation potentials towards cardiomocytes or vascular endothelial cells in vitro. This is indicated by higher expressions of cardiomyocyte and vascular endothelial cell mature markers in vitro. Furthermore, we identified that 24 proteins were down-regulated and 3 proteins were up-regulated in the 5(th) BM-MSCs in comparison to the 1(st) BM-MSCs, using mass spectrometry following two-dimensional electrophoresis. Our data suggest that transplantation of the 1(st) BM-MSCs may be an effective therapeutic strategy for cardiac tissue regeneration following AMI, and altered protein expression profiles between the 1(st) BM-MSCs and 5(th) passage BM-MSCs may account for the difference in their maintenance of stemness and their therapeutic effects following AMI.
C1 [Jin, Jianliang; Guo, Chun; Miao, Dengshun] Nanjing Med Univ, Res Ctr Bone & Stem Cells, Dept Anat Histol & Embryol, Nanjing, Jiangsu, Peoples R China.
   [Zhao, Yingming; Tan, Xiao; Yang, Zhijian] Nanjing Med Univ, Affiliated Hosp 1, Dept Cardiol, Nanjing, Jiangsu, Peoples R China.
RP Jin, JL (reprint author), Nanjing Med Univ, Res Ctr Bone & Stem Cells, Dept Anat Histol & Embryol, Nanjing, Jiangsu, Peoples R China.
EM zhijianyangnj@yahoo.com.cn; dsmiao@njmu.edu.cn
FU Jiangsu Foundation of Science and Technology [BK2006729]
FX This work was supported by Jiangsu Foundation of Science and Technology
   (no. BK2006729) to Z. Yang and D. Miao. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559
   Airey JA, 2004, CIRCULATION, V109, P1401, DOI 10.1161/01.CIR.0000124222.16321.26
   Avramidou A, 2007, CELL DEATH DIFFER, V14, P1936, DOI 10.1038/sj.cdd.4402206
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19-3-180
   Boiret N, 2003, EXP HEMATOL, V31, P1275, DOI 10.1016/j.exphem.2003.08.010
   Chen XD, 2007, J BONE MINER RES, V22, P1943, DOI 10.1359/JBMR.070725
   Dawn B, 2008, STEM CELLS, V26, P1646, DOI 10.1634/stemcells.2007-0715
   Feliers D, 2007, AM J PHYSIOL-RENAL, V293, pF607, DOI 10.1152/ajprenal.00497.2006
   Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com
   Guo YH, 2008, ARCH MED RES, V39, P179, DOI 10.1016/j.arcmed.2007.11.001
   Hipp J, 2004, J EXP CLIN ASSIST RE, V1, P3, DOI [10.1186/1743-1050-1-3, DOI 10.1186/1743-1050-1-3]
   Imanishi Y, 2008, J MOL CELL CARDIOL, V44, P662, DOI 10.1016/j.yjmcc.2007.11.001
   Jo JI, 2007, TISSUE ENG, V13, P313, DOI 10.1089/ten.2006.0133
   Kretlow JD, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-60
   Kucia M, 2006, LEUKEMIA, V20, P857, DOI 10.1038/sj.leu.2404171
   Li WZ, 2007, STEM CELLS, V25, P2118, DOI 10.1634/stemcells.2006-0771
   Liang GB, 2009, BIORESOURCE TECHNOL, V100, P350, DOI 10.1016/j.biortech.2008.06.012
   Lim SY, 2006, CARDIOVASC RES, V70, P530, DOI 10.1016/j.cardiores.2006.02.016
   Ling Q, 2004, J CLIN INVEST, V113, P38, DOI 10.1172/JCI200419684
   Lobe CG, 1999, DEV BIOL, V208, P281, DOI 10.1006/dbio.1999.9209
   Masuda Y, 2004, J BIOL CHEM, V279, P42503, DOI 10.1074/jbc.M404256200
   Menasche G, 2007, MOL CELL BIOL, V27, P4070, DOI 10.1128/MCB.02011-06
   Miao DS, 2002, J CLIN INVEST, V109, P1173, DOI 10.1172/JCI200214817
   Murry CE, 2005, CIRCULATION, V112, P3174, DOI 10.1161/CIRCULATIONAHA.105.546218
   Park JE, 2005, BIOCHEM BIOPH RES CO, V337, P1283, DOI 10.1016/j.bbrc.2005.10.004
   Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Popov BV, 2007, TISSUE ENG, V13, P2441, DOI 10.1089/ten.2007.0001
   Pountos I, 2007, INJURY, V38, pS23, DOI 10.1016/S0020-1383(08)70006-8
   Saegusa J, 2008, J INVEST DERMATOL, V128, P2403, DOI 10.1038/jid.2008.119
   Shih SC, 2002, AM J PATHOL, V161, P35, DOI 10.1016/S0002-9440(10)64154-5
   Shiota M, 2007, EXP CELL RES, V313, P1008, DOI 10.1016/j.yexcr.2006.12.017
   Siepe M, 2005, EUR J CARDIO-THORAC, V28, P318, DOI 10.1016/j.ejcts.2005.03.044
   Stolzing A, 2006, FREE RADICAL BIO MED, V41, P326, DOI 10.1016/j.freeradbiomed.2006.04.018
   Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C
   Strauer BE, 2001, DEUT MED WOCHENSCHR, V126, P932, DOI 10.1055/s-2001-16579-1
   Sun W, 2010, DEVELOPMENT, V137, P985, DOI 10.1242/dev.045898
   Tang YL, 2005, ANN THORAC SURG, V80, P229, DOI 10.1016/j.athoracsur.2005.02.072
   Valiunas V, 2004, J PHYSIOL-LONDON, V555, P617, DOI 10.1113/jphysiol.2003.058719
   Wang L, 2005, J MOL MED, V83, P812, DOI 10.1007/s00109-005-0676-y
   You Z, 2005, NUCLEIC ACIDS RES, V33, P3033, DOI 10.1093/nar/gki607
   Zhang DS, 2008, J MOL CELL CARDIOL, V44, P281, DOI 10.1016/j.yjmcc.2007.11.010
   Zhang ZL, 2009, BONE MARROW TRANSPL, V43, P69, DOI 10.1038/bmt.2008.260
   Zhu YF, 2006, J PROTEOME RES, V5, P2217, DOI 10.1021/pr0600733
NR 44
TC 20
Z9 23
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 17
PY 2011
VL 6
IS 6
AR e21005
DI 10.1371/journal.pone.0021005
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 778VR
UT WOS:000291737600037
PM 21698117
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Kawaguchi, N
   Smith, AJ
   Waring, CD
   Hasan, MK
   Miyamoto, S
   Matsuoka, R
   Ellison, GM
AF Kawaguchi, Nanako
   Smith, Andrew J.
   Waring, Cheryl D.
   Hasan, Md Kamrul
   Miyamoto, Shinka
   Matsuoka, Rumiko
   Ellison, Georgina M.
TI c-kit(pos) GATA-4 High Rat Cardiac Stem Cells Foster Adult Cardiomyocyte
   Survival through IGF-1 Paracrine Signalling
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR-I; REGENERATE INFARCTED MYOCARDIUM; BONE-MARROW-CELLS;
   PROGENITOR CELLS; HEART-FAILURE; MURINE HEART; APOPTOSIS; MECHANISMS;
   THERAPY; MULTIPOTENT
AB Background: Resident c-kit positive (c-kit(pos)) cardiac stem cells (CSCs) could be considered the most appropriate cell type for myocardial regeneration therapies. However, much is still unknown regarding their biological properties and potential.
   Methodology/Principal Findings: We produced clones of high and low expressing GATA-4 CSCs from long-term bulk-cultured c-kit(pos) CSCs isolated from adult rat hearts. When c-kit(pos) GATA-4 high expressing clonal CSCs (cCSCs) were co-cultured with adult rat ventricular cardiomyocytes, we observed increased survival and contractility of the cardiomyocytes, compared to cardiomyocytes cultured alone, co-cultured with fibroblasts or c-kit(pos) GATA-4 low expressing cCSCs. When analysed by ELISA, the concentration of IGF-1 was significantly increased in the c-kit(pos) GATA-4 high cCSC/cardiomyocyte co-cultures and there was a significant correlation between IGF-1 concentration and cardiomyocyte survival. We showed the activation of the IGF-1 receptor and its downstream molecular targets in cardiomyocytes co-cultured with c-kit(pos) GATA-4 high cCSCs but not in cardiomyocytes that were cultured alone, co-cultured with fibroblasts or c-kit(pos) GATA-4 low cCSCs. Addition of a blocking antibody specific to the IGF-1 receptor inhibited the survival of cardiomyocytes and prevented the activation of its signalling in cardiomyocytes in the c-kit(pos) GATA-4 high cCSC/cardiomyocyte co-culture system. IGF-1 supplementation or IGF-1 high conditioned medium taken from the co-culture of c-kit(pos) GATA-4 high cCSCs plus cardiomyocytes did extend the survival and contractility of cardiomyocytes cultured alone and cardiomyocytes co-cultured with c-kit(pos) GATA-4 low cCSCs.
   Conclusion/Significance: c-kit(pos) GATA-4 high cCSCs exert a paracrine survival effect on cardiomyocytes through induction of the IGF-1R and signalling pathway.
C1 [Kawaguchi, Nanako; Hasan, Md Kamrul; Miyamoto, Shinka; Matsuoka, Rumiko] Tokyo Womens Med Univ, IREIIMS, Tokyo, Japan.
   [Smith, Andrew J.; Waring, Cheryl D.; Ellison, Georgina M.] Liverpool John Moores Univ, Res Inst Sport & Exercise Sci, Stem Cell & Mol Physiol Lab, Liverpool L3 5UX, Merseyside, England.
   [Miyamoto, Shinka] Tokyo Womens Med Univ, Heart Inst Japan, Dept Cardiovasc Surg, Tokyo, Japan.
RP Kawaguchi, N (reprint author), Tokyo Womens Med Univ, IREIIMS, Tokyo, Japan.
EM g.m.ellison@ljmu.ac.uk
RI Ellison-Hughes, Georgina M./B-4597-2016
OI Ellison-Hughes, Georgina M./0000-0002-2733-3361
FU Ministry of Education, Culture, Sports, Science and Technology, Japan;
   British Heart Foundation [PG/06/053, PG 08/085]; European Community
   [PIRG02-GA-2007-224853]
FX This work was supported by the encouraging Development of Strategic
   Research Centers, Special Co-ordination Funds for Promoting Science and
   Technology and a Grant-in Aid for Scientific Research (A), Ministry of
   Education, Culture, Sports, Science and Technology, Japan; grants to G.
   M. E from the British Heart Foundation (PG/06/053; PG 08/085) and a
   Marie Curie International Reintegration Grant within the 7th European
   Community Framework Programme (PIRG02-GA-2007-224853). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Aoyama T, 2002, CARDIOVASC RES, V55, P787, DOI 10.1016/S0008-6363(02)00493-5
   Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460
   Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1
   Bernecker Oliver Y, 2003, Cardiovasc Toxicol, V3, P183, DOI 10.1385/CT:3:3:183
   Braunwald E, 2000, CIRCULATION, V102, P14
   BRAUNWALD E, 1991, AM J CARDIOL, V68, pD1
   Chien KR, 2004, NATURE, V428, P607, DOI 10.1038/nature02500
   Chimenti I, 2010, CIRC RES, V106, P971, DOI 10.1161/CIRCRESAHA.109.210682
   Davis ME, 2006, P NATL ACAD SCI USA, V103, P8155, DOI 10.1073/pnas.0602877103
   Ellison Georgina M, 2007, Nat Clin Pract Cardiovasc Med, V4 Suppl 1, pS52, DOI 10.1038/ncpcardio0773
   Ellison GM, 2007, J BIOL CHEM, V282, P11397, DOI 10.1074/jbc.M607391200
   Fu YC, 2004, CARDIOVASC RES, V62, P558, DOI 10.1016/j.cardiores.2004.01.039
   Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660
   Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826
   Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com
   Heineke J, 2007, J CLIN INVEST, V117, P3198, DOI 10.1172/JCI32573
   Janssens S, 2010, ANNU REV MED, V61, P287, DOI 10.1146/annurev.med.051508.215152
   KELLEY C, 1993, DEVELOPMENT, V118, P817
   Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC
   Kinnaird T, 2004, CIRCULATION, V109, P1543, DOI 10.1161/01.CIR.0000124062.31102.57
   Kubal C, 2006, J THORAC CARDIOV SUR, V132, P1112, DOI 10.1016/j.jtcvs.2006.06.028
   Lai VK, 2009, J THORAC CARDIOV SUR, V138, P1400, DOI 10.1016/j.jtcvs.2009.07.013
   LaVoie HA, 2004, ENDOCRINOLOGY, V145, P3122, DOI 10.1210/en.2003-1719
   Linke A, 2005, P NATL ACAD SCI USA, V102, P8966, DOI 10.1073/pnas.0502678102
   Martin-Rendon E, 2008, EUR HEART J, V29, P1807, DOI 10.1093/eurheartj/ehn220
   Matsuura K, 2004, J BIOL CHEM, V279, P11384, DOI 10.1074/jbc.M310822200
   Messina E, 2004, CIRC RES, V95, P911, DOI 10.1161/01.RES.0000147315.71699.51
   Miyamoto S, 2010, STEM CELLS DEV, V19, P105, DOI 10.1089/scd.2009.0041
   Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061
   Moore XL, 2007, ENDOCRINOLOGY, V148, P1582, DOI 10.1210/en.2006-1324
   Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446
   Nadal-Ginard B, 2006, REV ESP CARDIOL, V59, P1175
   Oka T, 2006, CIRC RES, V98, P837, DOI 10.1161/01.RES.0000215985.18538.c4
   Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587
   Padin-Iruegas ME, 2009, CIRCULATION, V120, P876, DOI 10.1161/CIRCULATIONAHA.109.852285
   Reffelmann T, 2009, J AM COLL CARDIOL, V53, P305, DOI 10.1016/j.jacc.2008.10.018
   Rosenblatt-Velin N, 2005, J CLIN INVEST, V115, P1724, DOI 10.1172/JCI23418
   Rota M, 2005, CIRC RES, V97, P1332, DOI 10.1161/01.RES.0000196568.11624.ae
   Sadat S, 2007, BIOCHEM BIOPH RES CO, V363, P674, DOI 10.1016/j.bbrc.2007.09.058
   Tang XL, 2010, CIRCULATION, V121, P293, DOI 10.1161/CIRCULATIONAHA.109.871905
   Tomita Y, 2005, J CELL BIOL, V170, P1135, DOI 10.1083/jcb.200504061
   Torella D, 2004, CIRC RES, V94, P514, DOI 10.1161/01.RES.0000117306.10142.50
   Torella Daniele, 2007, Nat Clin Pract Cardiovasc Med, V4 Suppl 1, pS46, DOI 10.1038/ncpcardio0772
   Wencker D, 2003, J CLIN INVEST, V111, P1497, DOI 10.1172/JCI200317664
   Wu S, 2002, J MOL CELL CARDIOL, V34, P1595, DOI 10.1006/jmcc.2002.2110
   Yamaoka M, 2000, J MOL CELL CARDIOL, V32, P881, DOI 10.1006/jmcc.2000.1132
   Yang L, 2008, NATURE, V453, P524, DOI 10.1038/nature06894
   Zaruba MM, 2010, CIRCULATION, V121, P1992, DOI 10.1161/CIRCULATIONAHA.109.909093
   Zhou X, 2010, CARDIOLOGY, V115, P243, DOI 10.1159/000301278
NR 49
TC 55
Z9 60
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 13
PY 2010
VL 5
IS 12
AR e14297
DI 10.1371/journal.pone.0014297
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 693SY
UT WOS:000285246900010
PM 21179204
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Wang, Y
   Abarbanell, AM
   Herrmann, JL
   Weil, BR
   Manukyan, MC
   Poynter, JA
   Meldrum, DR
AF Wang, Yue
   Abarbanell, Aaron M.
   Herrmann, Jeremy L.
   Weil, Brent R.
   Manukyan, Mariuxi C.
   Poynter, Jeffrey A.
   Meldrum, Daniel R.
TI TLR4 Inhibits Mesenchymal Stem Cell (MSC) STAT3 Activation and Thereby
   Exerts Deleterious Effects on MSC-Mediated Cardioprotection
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; TOLL-LIKE RECEPTORS; BONE-MARROW;
   MYOCARDIAL-INFARCTION; PROGENITOR CELLS; CARDIAC REPAIR;
   ISCHEMIA/REPERFUSION INJURY; CD34 EXPRESSION; CXC CHEMOKINES; STROMAL
   CELLS
AB Background: Bone marrow-derived mesenchymal stem cells (MSC) improve myocardial recovery after ischemia/reperfusion (I/R) injury. These effects are mediated in part by the paracrine secretion of angiogenic and tissue growth-promoting factors. Toll-like receptor 4 (TLR4) is expressed by MSC and induces apoptosis and inhibits proliferation in neuronal progenitors as well as many other cell types. It is unknown whether knock-out (KO) of TLR4 will change the paracrine properties of MSC and in turn improve MSC-associated myocardial protection.
   Methodology/Principal Findings: This study explored the effect of MSC TLR4 on the secretion of angiogenic factors and chemokines in vitro by using ELISA and cytokine array assays and investigated the role of TLR4 on MSC-mediated myocardial recovery after I/R injury in an isolated rat heart model. We observed that MSC isolated from TLR4 KO mice exhibited a greater degree of cardioprotection in a rat model of myocardial I/R injury. This enhanced protection was associated with increased angiogenic factor production, proliferation and differentiation. TLR4-dificiency was also associated with decreased phosphorylation of PI-3K and AKT, but increased activation of STAT3. siRNA targeting of STAT3 resulted in attenuation of the enhanced cardioprotection of TLR4-deficient MSC.
   Conclusions/Significance: This study indicates that TLR4 exerts deleterious effects on MSC-derived cardioprotection following I/R by a STAT3 inhibitory mechanism.
C1 [Wang, Yue; Abarbanell, Aaron M.; Herrmann, Jeremy L.; Weil, Brent R.; Manukyan, Mariuxi C.; Poynter, Jeffrey A.; Meldrum, Daniel R.] Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA.
   [Meldrum, Daniel R.] Indiana Univ Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN USA.
   [Meldrum, Daniel R.] Indiana Univ Sch Med, Ctr Immunobiol, Indianapolis, IN USA.
RP Wang, Y (reprint author), Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA.
EM dmeldrum@iupui.edu
FU NIH [R01GM070628, R01HL085595, F32 HL092718, F32 HL092719, F32 HL093987]
FX This work was supported in part by the following NIH grants:
   R01GM070628, R01HL085595, F32 HL092718, F32 HL092719 and F32 HL093987.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Arminan A, 2010, J AM COLL CARDIOL, V55, P2244, DOI 10.1016/j.jacc.2009.08.092
   Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD
   Assmus B, 2006, NEW ENGL J MED, V355, P1222, DOI 10.1056/NEJMoa051779
   Belo AV, 2005, MICROCIRCULATION, V12, P597, DOI 10.1080/10739680500253535
   Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1
   Boyle AJ, 2010, METHODS MOL BIOL, V660, P65, DOI 10.1007/978-1-60761-705-1_5
   Copland I, 2008, EXP HEMATOL, V36, P93, DOI 10.1016/.i.exphem.2007.08.032
   Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838
   Dill T, 2009, AM HEART J, V157, P541, DOI 10.1016/j.ahj.2008.11.011
   Edman LC, 2008, EXP CELL RES, V314, P2123, DOI 10.1016/j.yexcr.2008.02.019
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Filipovic R, 2008, GLIA, V56, P1, DOI 10.1002/glia.20582
   Frangogiannis NG, 2004, CIRCULATION, V110, P1341, DOI 10.1161/01.CIR.0000141560.18364.63
   Gnecchi M, 2005, NAT MED, V11, P367, DOI 10.1038/nm0405-367
   Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com
   Gosse SG, 2005, CELL SIGNAL, V17, P1352, DOI 10.1016/j.cellsig.2005.02.002
   Guedez L, 1998, BLOOD, V92, P1342
   Haider HK, 2005, AM J PHYSIOL-HEART C, V288, pH2557, DOI 10.1152/ajpheart.01215.2004
   Hossain M, 2005, BIOMATERIALS, V26, P2595, DOI 10.1016/j.biomaterials.2004.07.051
   Hua F, 2009, BRAIN RES, V1262, P100, DOI 10.1016/j.brainres.2009.01.018
   Huang J, 2010, CIRC RES, V106, P1753, DOI 10.1161/CIRCRESAHA.109.196030
   Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043
   Jung DY, 2005, J IMMUNOL, V174, P6467, DOI 10.4049/jimmunol.174.10.6467
   Krampera M, 2003, BLOOD, V101, P3722, DOI 10.1182/blood-2002-07-2104
   Kudo M, 2003, J MOL CELL CARDIOL, V35, P1113, DOI 10.1016/S0022-2828(03)00211-6
   Loberg RD, 2007, NEOPLASIA, V9, P556, DOI 10.1593/neo.07307
   Markel TA, 2008, AM J PHYSIOL-REG I, V295, pR1124, DOI 10.1152/ajpregu.90508.2008
   Min JK, 2005, CIRC RES, V96, P300, DOI 10.1161/01.RES.0000155330.07887.EE
   Nesselmann C, 2008, J CELL MOL MED, V12, P1795, DOI 10.1111/j.1582-4934.2008.00457.x
   Nourse MB, ARTERIOSCLER THROMB, V30, P80
   Osada-Oka M, 2008, J ATHEROSCLER THROMB, V15, P26, DOI 10.5551/jat.E533
   Pevsner-Fischer M, 2007, BLOOD, V109, P1422, DOI 10.1182/blood-2006-06-028704
   Rho SB, 2007, J CELL BIOCHEM, V101, P57, DOI 10.1002/jcb.21127
   Rolls A, 2007, NAT CELL BIOL, V9, P1081, DOI 10.1038/ncb1629
   Romagnani P, 2004, TRENDS IMMUNOL, V25, P201, DOI 10.1016/j.it.2004.02.006
   Sanchez-Tillo E, 2006, EUR J IMMUNOL, V36, P2515, DOI 10.1002/eji.200535270
   Shechter R, 2008, J CELL BIOL, V183, P393, DOI 10.1083/jcb.200804010
   SIMMONS PJ, 1991, BLOOD, V78, P2848
   Stamatovic SM, 2006, J IMMUNOL, V177, P2651, DOI 10.4049/jimmunol.177.4.2651
   Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C
   Takahashi Y, 2005, J BIOL CHEM, V280, P24195, DOI 10.1074/jbc.M411913200
   Togel F, 2005, AM J PHYSIOL-RENAL, V289, pF31, DOI 10.1152/ajprenal.00007.2005
   Tomchuck SL, 2008, STEM CELLS, V26, P99, DOI 10.1634/stemcells.2007-0563
   Trivedi P, 2010, STEM CELLS DEV, V19, P1109, DOI 10.1089/scd.2009.0465
   Tsung A, 2005, J IMMUNOL, V175, P7661, DOI 10.4049/jimmunol.175.11.7661
   WALLER EK, 1995, BLOOD, V86, P710
   Wang MJ, 2007, J MOL CELL CARDIOL, V42, P1009, DOI 10.1016/j.yjmcc.2007.04.010
   Wang MJ, 2009, P NATL ACAD SCI USA, V106, P17499, DOI 10.1073/pnas.0908924106
   Wang MJ, 2009, J THORAC CARDIOV SUR, V138, P163, DOI 10.1016/j.jtcvs.2009.03.010
   Wang Y, 2008, AM J PHYSIOL-REG I, V295, pR1115, DOI 10.1152/ajpregu.90383.2008
   Wang Y, 2009, AM J PHYSIOL-CELL PH, V297, pC1284, DOI 10.1152/ajpcell.00183.2009
   Wang Y, 2009, SURGERY, V146, P198, DOI 10.1016/j.surg.2009.04.013
   Weil BR, 2009, AM J PHYSIOL-REG I, V296, pR1735, DOI 10.1152/ajpregu.90876.2008
   Weimar IS, 1998, LEUKEMIA, V12, P1195, DOI 10.1038/sj.leu.2401080
   Wollert KC, 2004, LANCET, V364, P141, DOI 10.1016/S0140-6736(04)16626-9
   Wu HL, 2007, J CLIN INVEST, V117, P2847, DOI 10.1172/JCI31008
   Zeller CN, 2009, ANN THORAC SURG, V87, P812, DOI 10.1016/j.athoracsur.2008.12.033
NR 57
TC 2
Z9 3
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 3
PY 2010
VL 5
IS 12
AR e14206
DI 10.1371/journal.pone.0014206
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 689PF
UT WOS:000284939600003
PM 21151968
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Cao, F
   Wagner, RA
   Wilson, KD
   Xie, XY
   Fu, JD
   Drukker, M
   Lee, A
   Li, RA
   Gambhir, SS
   Weissman, IL
   Robbins, RC
   Wu, JC
AF Cao, Feng
   Wagner, Roger A.
   Wilson, Kitchener D.
   Xie, Xiaoyan
   Fu, Ji-Dong
   Drukker, Micha
   Lee, Andrew
   Li, Ronald A.
   Gambhir, Sanjiv S.
   Weissman, Irving L.
   Robbins, Robert C.
   Wu, Joseph C.
TI Transcriptional and Functional Profiling of Human Embryonic Stem
   Cell-Derived Cardiomyocytes
SO PLOS ONE
LA English
DT Article
ID HUMAN BLASTOCYSTS; CARDIAC MYOCYTES; DIFFERENTIATION; EXPRESSION;
   NETWORKS; REPAIR; HEART; PLURIPOTENCY; MYOCARDIUM; PROTECTION
AB Human embryonic stemcells (hESCs) can serve as a potentially limitless source of cells that may enable regeneration of diseased tissue and organs. Here we investigate the use of human embryonic stem cell-derived cardiomyocytes (hESC-CMs) in promoting recovery from cardiac ischemia reperfusion injury in a mouse model. Using microarrays, we have described the hESC-CM transcriptome within the spectrum of changes that occur between undifferentiated hESCs and fetal heart cells. The hESC-CMs expressed cardiomyocyte genes at levels similar to those found in 20-week fetal heart cells, making this population a good source of potential replacement cells in vivo. Echocardiographic studies showed significant improvement in heart function by 8 weeks after transplantation. Finally, we demonstrate long-term engraftment of hESC-CMs by using molecular imaging to track cellular localization, survival, and proliferation in vivo. Taken together, global gene expression profiling of hESC differentiation enables a systems-based analysis of the biological processes, networks, and genes that drive hESC fate decisions, and studies such as this will serve as the foundation for future clinical applications of stem cell therapies.
C1 [Cao, Feng; Wilson, Kitchener D.; Xie, Xiaoyan; Lee, Andrew; Gambhir, Sanjiv S.; Wu, Joseph C.] Stanford Univ, Sch Med, Dept Radiol, Stanford, CA 94305 USA.
   [Wagner, Roger A.; Wu, Joseph C.] Stanford Univ, Sch Med, Dept Med, Div Cardiol, Stanford, CA 94305 USA.
   [Wilson, Kitchener D.; Gambhir, Sanjiv S.] Stanford Univ, Sch Med, Dept Bioengn, Stanford, CA 94305 USA.
   [Drukker, Micha; Weissman, Irving L.] Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA.
   [Robbins, Robert C.] Stanford Univ, Sch Med, Dept Cardiothorac Surg, Stanford, CA 94305 USA.
   [Fu, Ji-Dong; Li, Ronald A.] Univ Calif Davis, Dept Cell Biol & Human Anat, Stem Cell Program, Davis, CA USA.
RP Cao, F (reprint author), Stanford Univ, Sch Med, Dept Radiol, Stanford, CA 94305 USA.
EM joewu@stanford.edu
RI Wilson, Kitchener/A-7146-2016; Li, Ronald/E-9833-2010; Fu,
   Jidong/E-8173-2012
OI Fu, Jidong/0000-0003-2797-5193
FU BWF CAMS; Stanford Cardiovascular Institute; NIH [HL089027, CA114747,
   HL076445, HL72857]; CIRM [RS1-00322]
FX This work was supported by grants from the BWF CAMS, Stanford
   Cardiovascular Institute, NIH HL089027, and CIRM RS1-00322 (JCW). This
   work was also supported in part by NIH CA114747 (SSG), NIH HL076445
   (RAW), and NIH HL72857 (RAL).
CR Baker NL, 2007, ANN NEUROL, V62, P390, DOI 10.1002/ana.21213
   Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460
   Beqqali A, 2006, STEM CELLS, V24, P1956, DOI 10.1634/stemcells.2006-0054
   Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1
   Collins KA, 2003, PHYSIOL GENOMICS, V13, P227, DOI 10.1152/physiolgenomics.00005.2003
   CROTTI L, 2007, HUM GENET, V120, P912
   Eschenhagen T, 2005, CIRC RES, V97, P1220, DOI 10.1161/01.RES.0000196562.73231.7d
   Gambhir SS, 1999, NUCL MED BIOL, V26, P481, DOI 10.1016/S0969-8051(99)00021-9
   Gnecchi M, 2005, NAT MED, V11, P367, DOI 10.1038/nm0405-367
   Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com
   He JQ, 2003, CIRC RES, V93, P32, DOI 10.1161/01.RES.0000080317.92718.99
   Hentschke M, 2006, J BIOL CHEM, V281, P33497, DOI 10.1074/jbc.M606975200
   Holaska JM, 2006, HUM MOL GENET, V15, P3459, DOI 10.1093/hmg/ddl423
   HOU D, 2005, CIRCULATION, V112, P1150
   Kehat I, 2002, CIRC RES, V91, P659, DOI 10.1161/01.RES.0000039084.30342.9B
   Kehat I, 2001, J CLIN INVEST, V108, P407, DOI 10.1172/JCI12131
   Laflamme MA, 2007, NAT BIOTECHNOL, V25, P1015, DOI 10.1038/nbt1327
   Lee CS, 2005, NATURE, V435, P944, DOI 10.1038/nature03649
   LEOR J, 2007, HEART, V12, P12
   Leor J, 2007, HEART, V93, P1278, DOI 10.1136/hrt.2006.093161
   Li L, 1997, DEV BIOL, V187, P311, DOI 10.1006/dbio.1997.8621
   Lincoln J, 2007, DEV BIOL, V305, P120, DOI 10.1016/j.ydbio.2007.02.002
   Luo XB, 2007, J CELL PHYSIOL, V212, P358, DOI 10.1002/jcp.21030
   Masaki H, 2007, J BIOL CHEM, V282, P33034, DOI 10.1074/jbc.M703245200
   McMartin GA, 2003, J ANAT, V203, P369, DOI 10.1046/j.1469-7580.2003.00228.x
   Meyn MA, 2005, MOL PHARMACOL, V68, P1320, DOI 10.1124/mol.104.010231
   Michele DE, 2002, CIRC RES, V91, P255, DOI 10.1161/01.RES.0000027530.58419.82
   Mirotsou M, 2007, P NATL ACAD SCI USA, V104, P1643, DOI 10.1073/pnas.0610024104
   Miyoshi H, 1998, J VIROL, V72, P8150
   Mummery C, 2003, CIRCULATION, V107, P2733, DOI 10.1161/01.CIR.0000068356.38592.68
   MURAGAKI Y, 1991, EUR J BIOCHEM, V197, P615, DOI 10.1111/j.1432-1033.1991.tb15951.x
   Newton-Cheh C, 2007, CIRCULATION, V116, P1128, DOI 10.1161/CIRCULATIONAHA.107.710780
   Pan GJ, 2007, CELL RES, V17, P42, DOI 10.1038/sj.cr.7310125
   PFEFFER MA, 1995, ANNU REV MED, V46, P455, DOI 10.1146/annurev.med.46.1.455
   Plaisier E, 2007, NEW ENGL J MED, V357, P2687, DOI 10.1056/NEJMoa071906
   Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399
   Schulz WA, 2007, EPIGENETICS, V2, P37, DOI 10.4161/epi.2.1.4067
   Synnergren J, 2008, STEM CELLS, V26, P1831, DOI 10.1634/stemcells.2007-1033
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   van Laake LW, 2008, CIRC RES, V102, P1008, DOI 10.1161/CIRCRESAHA.108.175505
   VANAMERONGEN MJ, 2008, J CELLULAR IN PRESS
   Wagner RA, 2005, DEV BIOL, V288, P595, DOI 10.1016/j.ydbio.2005.09.036
   WEBB GC, 1993, GENOMICS, V18, P464, DOI 10.1006/geno.1993.1505
   Xu CH, 2002, CIRC RES, V91, P501, DOI 10.1161/01.RES.0000035254.80718.91
   Yang L, 2008, NATURE, V453, P524, DOI 10.1038/nature06894
NR 46
TC 149
Z9 152
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 22
PY 2008
VL 3
IS 10
AR e3474
DI 10.1371/journal.pone.0003474
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 432IG
UT WOS:000265126100005
PM 18941512
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Parekkadan, B
   van Poll, D
   Suganuma, K
   Carter, EA
   Berthiaume, F
   Tilles, AW
   Yarmush, ML
AF Parekkadan, Biju
   van Poll, Daan
   Suganuma, Kazuhiro
   Carter, Edward A.
   Berthiaume, Francois
   Tilles, Arno W.
   Yarmush, Martin L.
TI Mesenchymal Stem Cell-Derived Molecules Reverse Fulminant Hepatic
   Failure
SO PLOS ONE
LA English
DT Article
AB Modulation of the immune system may be a viable alternative in the treatment of fulminant hepatic failure (FHF) and can potentially eliminate the need for donor hepatocytes for cellular therapies. Multipotent bone marrow-derived mesenchymal stem cells (MSCs) have been shown to inhibit the function of various immune cells by undefined paracrine mediators in vitro. Yet, the therapeutic potential of MSC-derived molecules has not been tested in immunological conditions in vivo. Herein, we report that the administration of MSC-derived molecules in two clinically relevant forms-intravenous bolus of conditioned medium (MSC-CM) or extracorporeal perfusion with a bioreactor containing MSCs (MSC-EB)-can provide a significant survival benefit in rats undergoing FHF. We observed a cell mass-dependent reduction in mortality that was abolished at high cell numbers indicating a therapeutic window. Histopathological analysis of liver tissue after MSC-CM treatment showed dramatic reduction of panlobular leukocytic infiltrates, hepatocellular death and bile duct duplication. Furthermore, we demonstrate using computed tomography of adoptively transferred leukocytes that MSC-CM functionally diverts immune cells from the injured organ indicating that altered leukocyte migration by MSC-CM therapy may account for the absence of immune cells in liver tissue. Preliminary analysis of the MSC secretome using a protein array screen revealed a large fraction of chemotactic cytokines, or chemokines. When MSC-CM was fractionated based on heparin binding affinity, a known ligand for all chemokines, only the heparin-bound eluent reversed FHF indicating that the active components of MSC-CM reside in this fraction. These data provide the first experimental evidence of the medicinal use of MSC-derived molecules in the treatment of an inflammatory condition and support the role of chemokines and altered leukocyte migration as a novel therapeutic modality for FHF.
C1 [Parekkadan, Biju; van Poll, Daan; Suganuma, Kazuhiro; Carter, Edward A.; Berthiaume, Francois; Tilles, Arno W.; Yarmush, Martin L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med & Surg Serv, Boston, MA 02115 USA.
   [Parekkadan, Biju; van Poll, Daan; Suganuma, Kazuhiro; Carter, Edward A.; Berthiaume, Francois; Tilles, Arno W.; Yarmush, Martin L.] Shriners Hosp Children, Boston, MA USA.
   [Parekkadan, Biju; Yarmush, Martin L.] Harvard Massachusetts Inst Technol, Div Hlth Sci & Technol, Cambridge, MA USA.
   [van Poll, Daan] Univ Utrecht, Univ Med Ctr, Dept Surg, Utrecht, Netherlands.
RP Yarmush, ML (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med & Surg Serv, Boston, MA 02115 USA.
EM ireis@sbi.org
FU National Science Foundation; Michael van Vlooten foundation; National
   Institutes of Health [K08 DK66040, K18 DK076819, R01 DK43371]; Shriners
   Hospitals for Children
FX BP was supported by a National Science Foundation predoctoral
   fellowship. DVP was supported by a fellowship from the Michael van
   Vlooten foundation. This work was partially supported by grants from the
   National Institutes of Health (K08 DK66040, K18 DK076819 and R01
   DK43371) and the Shriners Hospitals for Children.
CR Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559
   Beyth S, 2005, BLOOD, V105, P2214, DOI 10.1182/blood-2004-07-2921
   Dazzi F, 2006, BLOOD REV, V20, P161, DOI 10.1016/j.blre.2005.11.002
   Gnecchi M, 2005, NAT MED, V11, P367, DOI 10.1038/nm0405-367
   Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7
   Liechty KW, 2000, NAT MED, V6, P1282
   Maitra B, 2004, BONE MARROW TRANSPL, V33, P597, DOI 10.1038/sj.bmt.1704400
   Meisel R, 2004, BLOOD, V103, P4619, DOI 10.1182/blood-2003-11-3909
   PAREKKADAN B, 2007, BIOCH BIOPH IN PRESS
   Shinoda M, 2007, J SURG RES, V137, P130, DOI 10.1016/j.jss.2006.08.009
   Shinoda M, 2006, TISSUE ENG, V12, P1313, DOI 10.1089/ten.2006.12.1313
   Shito M, 2001, DIGEST DIS SCI, V46, P1700, DOI 10.1023/A:1010653504568
   Strain AJ, 2002, SCIENCE, V295, P1005, DOI 10.1126/science.1068660
   Zhang YM, 2004, STEM CELLS, V22, P1256, DOI 10.1634/stemcells.2004-0173
NR 15
TC 324
Z9 373
U1 0
U2 27
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 26
PY 2007
VL 2
IS 9
AR e941
DI 10.1371/journal.pone.0000941
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V10HT
UT WOS:000207455800020
PM 17895982
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

EF